THE PREBIOTIC INULIN BENEFICIALLY MODULATES THE GUT-BRAIN AXIS BY ENHANCING METABOLISM IN AN APOE4 MOUSE MODEL by Hoffman, Jared D.
University of Kentucky 
UKnowledge 
Theses and Dissertations--Pharmacology and 
Nutritional Sciences Pharmacology and Nutritional Sciences 
2018 
THE PREBIOTIC INULIN BENEFICIALLY MODULATES THE GUT-
BRAIN AXIS BY ENHANCING METABOLISM IN AN APOE4 MOUSE 
MODEL 
Jared D. Hoffman 
University of Kentucky, jdho253@g.uky.edu 
Author ORCID Identifier: 
https://orcid.org/0000-0002-9424-3526 
Digital Object Identifier: https://doi.org/10.13023/etd.2018.405 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Hoffman, Jared D., "THE PREBIOTIC INULIN BENEFICIALLY MODULATES THE GUT-BRAIN AXIS BY 
ENHANCING METABOLISM IN AN APOE4 MOUSE MODEL" (2018). Theses and Dissertations--
Pharmacology and Nutritional Sciences. 24. 
https://uknowledge.uky.edu/pharmacol_etds/24 
This Doctoral Dissertation is brought to you for free and open access by the Pharmacology and Nutritional Sciences 
at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Pharmacology and Nutritional 
Sciences by an authorized administrator of UKnowledge. For more information, please contact 
UKnowledge@lsv.uky.edu. 
STUDENT AGREEMENT: 
I represent that my thesis or dissertation and abstract are my original work. Proper attribution 
has been given to all outside sources. I understand that I am solely responsible for obtaining 
any needed copyright permissions. I have obtained needed written permission statement(s) 
from the owner(s) of each third-party copyrighted matter to be included in my work, allowing 
electronic distribution (if such use is not permitted by the fair use doctrine) which will be 
submitted to UKnowledge as Additional File. 
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and 
royalty-free license to archive and make accessible my work in whole or in part in all forms of 
media, now or hereafter known. I agree that the document mentioned above may be made 
available immediately for worldwide access unless an embargo applies. 
I retain all other ownership rights to the copyright of my work. I also retain the right to use in 
future works (such as articles or books) all or part of my work. I understand that I am free to 
register the copyright to my work. 
REVIEW, APPROVAL AND ACCEPTANCE 
The document mentioned above has been reviewed and accepted by the student’s advisor, on 
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of 
the program; we verify that this is the final, approved version of the student’s thesis including all 
changes required by the advisory committee. The undersigned agree to abide by the statements 
above. 
Jared D. Hoffman, Student 
Dr. Ai-Ling Lin, Major Professor 
Dr. Howard Glauert, Director of Graduate Studies 
THE PREBIOTIC INULIN BENEFICIALLY MODULATES THE 
GUT-BRAIN AXIS BY ENHANCING METABOLISM IN AN APOE4 
MOUSE MODEL  
 
 
 
 
 
_____________________________________ 
 
DISSERTATION 
_____________________________________ 
 
A dissertation submitted in partial fulfillment of the 
requirements for the degree of Doctor of Philosophy in the 
College of Medicine at the University of Kentucky 
 
By 
Jared David Hoffman 
 
Lexington, Kentucky 
 
Director: Dr. Ai-Ling Lin, Professor of Nutritional Sciences 
Co-Director: Dr. Ming Gong, Professor of Nutritional 
Sciences 
 
Lexington, Kentucky 
 
2018 
 
Copyright © Jared D. Hoffman 2018
 
 
 
 
 
 
 
 
ABSTRACT OF DISSERTATION 
 
 
 
 
 
THE PREBIOTIC INULIN BENEFICIALLY MODULATES THE GUT-BRAIN AXIS 
BY ENHANCING METABOLISM IN AN APOE4 MOUSE MODEL  
 
 
Alzheimer’s disease (AD) is the most common form of dementia and a growing 
disease burden that has seen pharmacological interventions primarily fail. 
Instead, it has been suggested that preventative measures such as a healthy 
diet may be the best way in preventing AD. Prebiotics are one such potential 
measure and are fermented into metabolites by the gut microbiota and acting as 
gut-brain axis components, beneficially impact the brain. However, the impact of 
prebiotics in AD prevention is unknown. Here we show that the prebiotic inulin 
increased multiple gut-brain axis components such as scyllo-inositol and short 
chain fatty acids in the gut, periphery, and in the case of scyllo-inositol, the brain. 
We found in E3FAD and E4FAD mice fed either a prebiotic or control diet for 4-
months, that the consumption of the prebiotic inulin can beneficially alter the gut 
microbiota, modulate metabolic function, and dramatically increase scyllo-inositol 
in the brain. This suggests that the consumption of prebiotics can beneficially 
impact the brain by enhancing metabolism, helping to decrease AD risk factors.  
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Chapter 1 Background  
 
1.1 Dissertation Overview 
 
 Alzheimer’s disease (AD) is the most common form of dementia with age 
being the greatest risk factor but with certain genetic differences also 
dramatically increasing one’s risk of developing this disease. These include 
having the Apolipoprotein 4 (APOE4) allele and Familial Alzheimer’s Disease 
(FAD) gene mutations. Recently, the gut-brain axis, or bi-directional 
communication between gut microbiota and brain, has become a topic of intense 
investigation. Indeed, the gut microbiome, or the trillions of bacteria in the gut, 
can be modulated to improve one’s health, including that of brain health. One 
way to modulate the gut microbiome is by the ingestion of prebiotics, the non-
digestible carbohydrates in certain foods that promote the growth of beneficial 
bacteria. One such prebiotic is inulin, a prominently studied prebiotic found in 
chicory root and other vegetables. We will test the hypothesis that modulating the 
gut microbiome with the prebiotic inulin will potentially prevent AD-like symptoms.  
 
1.2 Alzheimer’s Disease: Overview 
 
AD is a chronic neurological disorder originating in the hippocampus and 
frontal and temporal lobes and characterized by a progressive decline in one’s 
mental capabilities and cognition [1]. AD is the most common form of dementia 
with advanced age being the greatest risk factor [2]. As such, AD has become a 
growing health concern for society as the prevalence of this disease has 
concurred with the increasing age of the baby boomer population. Indeed, it is 
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anticipated that the population greater than 65 years of age will double between 
the years 2010 to 2050, according to the U.S. Census Bureau [3]. This is quite 
worrisome as the incidence of AD increases exponentially after the age of 65, 
and increases even more after the age of 90 [4]. With pharmacological 
interventions primarily failing, new preventive measures need to be utilized to 
prevent and delay the onset of this disease in those susceptible to AD [5]. 
Indeed, a recent study has indicated that preventative measures such as 
exercising, eating a healthful diet, and cognitive training may be an effective way 
to prevent AD [6].  
AD has two primary hallmarks. These are the formation of amyloid β (Aβ) 
plaques and neurofibrillary tangles (NFTs), or hyper phosphorylated tau. Usually, 
Aβ deposition precedes the formation of NFTs with accumulation beginning in 
the isocortical areas of the brain followed by the limbic and allocortical structures 
and lastly, progressing to the subcortical structures and cerebellar cortex [7]. 
Further, Aβ is a 36-43 amino acid peptide cleaved from amyloid precursor 
protein (APP) by the successive cleavage of β- and γ-secretases [7]. These form 
intermediate soluble oligomers and insoluble β-sheet pleated amyloid fibrils that 
are the primary components of extracellular Aβ plaques. These plaques may be 
diffuse, amorphous wisps of amyloid without a central core not associated with 
AD, or dense-core plaques, composed of a dense Thioflavin-S-(ThioS-) positive 
core and are associated with the progression of AD. Dystrophic neuritis and 
activated microglial cells and astrocytes also usually surround dense-core 
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plaques and are most pronounced in the cerebral cortex and hippocampus of the 
brain [7].  
The second hallmark, tau, is an intracellular microtubule protein that 
supports axonal transport via stabilization of microtubules. However, in AD, tau 
is hyper phosphorylated and aggregates, forming NFTs. NFTs originate in the 
medial temporal lobes and hippocampus with eventual spread to the neocortex 
[7]. They have a spatiotemporal progression that is associated with the severity 
of cognitive decline. Though generally thought of as the intracellular hallmark, 
these tangles can become extracellular when neurons die. Aside from these two 
primary AD hallmarks, other notable characteristics of AD include neuronal and 
synapse loss and cognitive decline, ultimately leading to dementia [7].  
The single greatest risk factor for AD is increased age [8]. However, other 
risk factors include high blood pressure, hypercholesterolemia, Type-2 diabetes 
(T2D), and the female gender. After the age of 75, females exhibit a 2-fold 
greater risk of AD compared to men, perhaps due to lack of estrogen [8]. 
However, the greatest genetic risk factor that increases one’s risk of developing 
AD is the apolipoprotein E4 (APOE4) allele, while other genetic risk factors 
include the Familial Alzheimer’s Disease (FAD) genetic mutations [8]. 
 
1.2.1 Genetic Risk Factors 
 
Genetic risk factors for AD include the FAD mutations. These are 
mutations in the APP, presenilin 1 (PSEN1), and/or presenilin 2 (PSEN2) genes 
that lead to early onset Familial Alzheimer’s Disease [9]. These mutations cause 
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increased cleavage by γ-secretase and formation of the 42 amino acid Aβ 
isoform, which aggregates more readily than the 40 amino acid form. As a 
clinical diagnostic marker, the 42/40 amino acid ratio of Aβ can predict the age of 
onset of AD [10].  
The greatest genetic risk factor towards AD is the APOE4 allele. APOE is 
a class of proteins essential for the transport and catabolism of triglyceride-rich 
lipoprotein among certain cells and tissues. In fact, APOE is primarily 
synthesized and secreted in the liver but is also produced in the brain, adrenal 
glands, testis, and skin. It has a strong affinity for lipids and phospholipids and 
may become lipidated through interactions with the cell surface or secretory 
vesicles [11]. APOE has three isoforms in humans: APOE2, protective against 
AD, APOE3, neutral towards AD, and APOE4, increases one’s risk of developing 
AD. Notably, the allele frequencies vary considerably in the human population. 
APOE3 is the most common at 77%, followed by APOE4 at 15%, and APOE2 at 
8% of the population. Intriguingly, APOE2 and APOE4 only vary from APOE3 by 
a single amino acid substitution in this 299-amino acid protein. Indeed, APOE2 
contains a cysteine at 112 and 158, APOE3 contains a cysteine at 112 and an 
arginine at 118, and APOE4 contains arginine at both 112 and 158 [12]. 
However, this substitution has a profound effect on the individual towards the 
development of AD, cerebral amyloid angiopathy, amyloid deposition in blood 
vessels, and recovery from cerebral trauma [11].  
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1.2.2 APOE4 Risk Factors 
  
Despite APOE4 and APOE3 only being different by a single amino acid, 
APOE4 can increase one’s risk of developing AD dependently and 
independently of Aβ. Dependently of Aβ, APOE4 may increase AD risk because 
of the differences in the affinity for Aβ due its lipid-binding domain [13]. This lipid-
binding domain is located on the C-terminus of APOE, whereas the N-terminus 
houses the amino acid differences between APOE3 and APOE4. This suggests 
the C- and N-terminus regions interact affecting what APOE3 and APOE4 
preferentially bind, including the isoform differences displayed when binding to 
the Aβ peptide. Indeed, APOE4 binds more rapidly to Aβ and even appears to 
enhance zinc- and copper-induced Aβ aggregation compared to APOE3 [14]. 
However, this binding of APOE4 to Aβ may depend upon its lipidation state 
including whether or not it is purified, lipid-poor, reconstituted with HDL lipids, or 
originated from astrocytes, cerebral spinal fluid (CSF), or serum. In general, it is 
also thought that APOE4 is less lipidated than APOE3 with an increased chance 
of being in an intermediate molten globule state, an unstable form [15]. This 
would provide less surface area for Aβ to interact with. Further confirming this in 
one study using mice, soluble APOE4/Aβ complex levels were decreased and 
had less stability compared to APOE3. It was also discovered that oligomerized 
Aβ was increased in APOE4 mice compared to APOE3 mice [16]. However, the 
APOE4 may not only complex with Aβ more effectively than APOE3, as 
previously mentioned, but also appears to decrease Aβ clearance from the brain, 
leading to increased plaque formation [11]. Overall, it appears the APOE4/Aβ 
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complex is less lipidated and stable than that of APOE3 in vitro, potentially 
increasing oligomerized Aβ levels but decreasing Aβ clearance and thus, 
increasing the risk of AD. 
Aβ-independent mechanisms by which APOE4 increases one’s risk of AD 
include inducing synaptic and cholinergic deficits, behavior dysfunction, and 
impairment of GABAergic interneurons. However, the primary cause of APOE4 
related AD deficits might be via fragmentation from proteolytic cleavage that may 
originally be prompted by brain stressors or injury [11]. Indeed, APOE4 is more 
susceptible to proteolytic cleavage than APOE3 [17]. These carboxyl-terminal-
truncated fragments enter the cell, wreaking havoc on organelles including that 
of tau and other cytoskeletal components. They have even been demonstrated 
in vitro to increase the formation of neurofibrillary tangles and appear to lead to 
mitochondrial dysfunction. Our lab has previously demonstrated in APOE4 
mouse models that cerebral glucose metabolism is decreased [18] and these 
truncated fragments may be one potential cause of this in APOE4 allele carrier. 
Another notable experiment in human studies found that APOE4 allele carriers 
had decreased cerebral blood flow (CBF) before AD-like symptoms occurred 
[19]. One reason this may potentially occur was explained in a study 
demonstrating that APOE4 leads to increased blood brain barrier (BBB) 
permeability via activation of the Cyclophilin A (CypA)-Nuclear Factor-κ-B 
(NFκB)-Metalloproteinase 9 (MMP-9) pathway in pericytes in the BBB [20]. The 
APOE4 allele promotes this inflammatory pathway by inhibiting low-density 
lipoprotein receptor-related protein 1 (LRP1) function, which maintains CypA 
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levels. In contrast, APOE3 normally stimulates LRP-1 activity. Thus, APOE4 
increases the pathway in which MMP-9 leads to tight junction barrier degradation 
via decreased protein expression of ZO-1, occludin, and claudin, basement 
membrane degradation, increased BBB permeability, and decreased CBF [20]. 
Collectively, the APOE4 allele can increase one’s AD risk through mechanisms 
dependent and independent of Aβ.  
 
1.2.3 APOE4 on Host Metabolism 
  
Carriers of the APOE4 allele also appear to have an altered metabolism. 
Indeed, APOE4 allele preferentially binds to large very low-density lipoprotein 
cholesterol (VLDL) particles and the APOE genotypes account for interindividual 
differences in lipid and lipoprotein levels [21]. The allele is even associated with 
a less desirable lipid profile that includes increased low-density lipoprotein 
cholesterol (LDL-C) levels and risk for coronary heart disease [22]. The APOE4 
allele also appears to play a role in glucose metabolism where APOE4 carriers 
have decreased cerebral metabolic rate of glucose, even in young adults [23]. In 
an AD mouse model utilizing the APOE4 allele, mitochondrial dysfunction began 
as early as 3-months in the mice [24]. Further in an AD mouse model utilizing the 
APOE4 allele and a mutation in APP, the APOE4 mice had greater impairment 
of insulin signaling compared to the APOE3 mice [25]. Another study even 
suggested that the APOE4 allele may interact with the insulin receptor less than 
that of the APOE3 allele [26]. Next, other alterations in the brain have also been 
found such as in one study by Johnson et al. that found APOE4 mice to have 
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alterations in hippocampal metabolites involved in purine, glutamate, 
glycerophospholipid (GPL), and pentose phosphate pathway metabolism [27]. 
Collectively, the APOE4 allele appears to lead to mitochondrial dysfunction and 
deleterious alterations in glucose and lipid metabolism. 
 
1.2.4 APOE Mouse Models 
 
One of the more effective ways of understanding the isoform effects 
caused by the APOE4 and APOE3 alleles on AD pathology is by using APOE 
transgenic mouse models [28]. In their history, APOE knock out models were 
initially utilized in an attempt to understand the effect of APOE in the brain. 
However, due to the differences in mouse and human APOE, this had severe 
shortcomings for translating these studies to humans. Indeed, the homology of 
mouse and human APOE is only 70%. Thus, to expand this research, mouse 
models that expressed APOE specifically in glia or neurons through 
heterologous promoters were utilized. These include glial fibrillar acidic protein 
(GFAP, GFAP-APOE) and neuron-specific enolase (NSE, NSE-APOE). 
Unfortunately, heterologous promoters are not as well-regulated as endogenous 
promoters for a few reasons: protein expression and copy number of the 
transgene is not as well controlled, and evidence suggests glia, not neurons, 
primarily express APOE. Thus, mouse models using knock-in, or target 
replacement (TR), of human APOE utilizing endogenous promoters for 
expression of APOE were generated. APOE-TR models have glial cells that 
express human APOE at physiological levels, replacing mouse APOE, a huge 
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advantage over previous models. Next, APOE-deficient and APOE-TR models 
were crossed with those that express human FAD mutations, including mutations 
in APP and/or PS1, with the goal of examining the effects of various human 
APOE isoforms on Aβ deposition [28]. The human FAD models are generally 
designated Aβ-Tg and include PDAPP (APPV717F), J9 (PS1M146V,L286V, APPV717F), 
and 5xFAD (APPK670N,M671L,I716V,V717I, PS1M146V,L286V), the latter having a more 
rapid onset of AD pathology than the two former. Typically, Aβ-Tg models 
develop plaque formation by 6-months of age; however, 5xFAD mice develop 
plaques by 2-months of age. When target replacement human APOE3 or 
APOE4 is added to 5xFAD mice (EFAD), plaque formation is delayed by 4 
months. Due to this delay in plaque deposition, the EFAD model offers an easier 
and more tractable ability to analyze plaque accumulation in the presence of 
human APOE alleles and the progression thereof. The EFAD model is also 
advantageous for studying markers related to AD, analyzing Aβ plaque formation 
via regional and temporal comparisons in the brain, and using interventions that 
may be more translatable to humans than previously mentioned AD mouse 
models [28].  
The mouse model that is the focus of this dissertation is the EFAD mouse 
model (E3FAD and E4FAD) that utilizes mice with the C57BL/6 background that 
are a cross of transgenic mice that overexpress human Aβ via 5 FAD (5xFAD) 
mutations and mice that express either the target replacement human APOE3 or 
APOE4 gene. This recent model was developed by Dr. Mary Jo LaDu in 2012 
[29]. The first study featuring this model described the synergistic effects of 
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APOE4 and Aβ. In mice with FAD mutations, amyloid deposits develop as early 
as 2-months of age [30]. However, the addition of APOE4 delayed amyloid 
deposition [31]. This holds true in this E4FAD model as the mice in this study 
demonstrated changes in Aβ buildup starting between 2- to 6-months of age, 
with E4FAD have greater total Aβ levels and Aβ42 compared to E3FAD mice. 
Specifically, total Aβ42 was greater in the hippocampus and cortex of APOE4 
mice compared to APOE3 but levels remained the same in the cerebellum. Next, 
E4FAD mice had significantly greater plaque deposition than E3FAD mice in the 
frontal cortex and subiculum at 4-months of age and in the frontal cortex at 6-
months of age. Interestingly, the E4FAD mice had significantly greater amounts 
of dense-core plaques while the E3FAD mice had more diffuse plaques. APOE4 
levels were significantly lower than APOE3 in the cerebellum at 4-months of age, 
the cortex at 2-, 4-, and 6-months of age, and the hippocampus at 2- and 4-
months of age. Overall, APOE levels were greatest in the cortex and 
hippocampus, regions susceptible to Aβ deposition, and lowest in the 
cerebellum, a brain region resistant to Aβ, with APOE4 levels lower than APOE3 
in each brain region at each time point. Quite importantly, soluble Aβ42 and 
soluble oligomeric Aβ levels, both associated with AD progression, were higher 
in the APOE4 mice compared to the APOE3 mice at 6-months of age. Based on 
these findings, the authors concluded that in the E4FAD mice, the decreased 
total APOE4 but increased Aβ42 levels is indicative that APOE4 promotes Aβ 
accumulation in the hippocampus and cortex. However, this is due to the 
function of APOE4, not the quantity thereof [29].  
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Other studies using the EFAD transgenic mice have found additional 
genotype effects. Rodriguez et al. found that E4FAD mice have more prominent 
plaques via Aβ staining than the E3FAD mice along with more dense plaques in 
the subiculum. Interestingly, the E4FAD mice had much greater cortical levels of 
IL-1β, a proinflammatory cytokine, in the cortex compared to E3FAD mice. 
E4FAD mice also exhibited increased measures of microglia reactivity and 
dystrophy in the cortex along with a genotype effect on the number of microglial 
cells surroundings plaques. Further, E4FAD mice had significantly greater 
average microglial cells surrounding plaques compared to APOE3. Collectively, 
this study showed that E4FAD mice have increased microglial and cytokine 
activation compared to E3FAD mice [32].   
EFAD mice have displayed genotype differences in cognition. Liu et al. 
demonstrated that female E4FAD mice at 2-, 4-, and 6-months of age displayed 
an intensified age-dependent decline in the Morris water maze test compared to 
E3FAD mice, indicative of diminishing long-term reference memory, spatial 
learning, and working memory. The E4FAD also demonstrated an age-
dependent decline in the Y-maze, unlike the E3FAD mice, indicative of decaying 
spatial recognition memory. Similar to other aforementioned studies, the total 
APOE levels were decreased in E4FAD mice compared to E3FAD. Next, the 
E4FAD mice in this study also have reduced post-synaptic protein levels, N-
methyl-D-aspartate receptor (NMDAR) levels, and brain-derived neurotropic 
factor (BDNF) levels at 6-months of age, which likely contribute to the cognitive 
deficits seen in E4FAD mice [33].  
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Other studies in E4FAD and E3FAD mice demonstrate that female 
E4FAD mice had greater cerebral cortex microbleeds and hemosiderin, an iron-
storage compound that is often formed after bleeding, than male E4FAD mice. 
The authors looked for similar effects in human APOE4 patients but found no 
sex differences [34]. Although interesting, there may be limitations to the EFAD 
mouse model in its translatability to humans. One limitation of this model is the 
lack of development of tau pathology typically seen in AD. However, Zhou et al. 
demonstrated that E4FAD mice had greater site-specific tau phosphorylation, 
potentially due to calpain-CDK5 signaling, compared to E3FAD mice [35]. 
Although the tau phosphorylation is more restrained in this study then typically 
seen in AD, it is notable that APOE4 and/or FAD mutations lead to increased tau 
phosphorylation.  
Next, Teter et al. demonstrated in a recent study that E4FAD mice, 
compared to E3FAD mice, had reduced miR146a, a microRNA in the brain and 
plasma that is increased in AD patients and helps regulate the inflammatory 
process by down regulating NFκB. Thus, it acts to decrease inflammation. The 
FAD mutations increase miR146a, however, the APOE4 allele appears to inhibit 
this process compared to the APOE3 allele, increasing the inflammatory 
process.  Here, we see genotype differences in the inflammatory process 
independent of Aβ in an EFAD mouse model [36]. Female E4FAD mice were 
treated with epidermal growth factor (EGF), which prevented cognitive decline, 
decreased microbleeds, and limited cerebrovascular dysfunction. Interestingly, 
the female E4FAD mice had greater cognitive impairment, lower EGF serum 
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levels, and greater microbleeds than their male counterparts. It is unclear why 
E4FAD female mice have such an exacerbated response, but the authors 
attribute this to increased extracellular Aβ exhibited in female mice and/or an 
enhanced inflammatory response in the brain [37]. Finally, a recent study by 
Abdullah et. al. investigating the effect of the APOE genotype on blood 
phospholipids found that E4FAD mice had a greater plasma arachidonic 
acid/docosahexaenoic acid (DHA) ratio, a ratio associated with increased 
inflammation, compared to the E3FAD mice. This was further confirmed in 
human subjects, where this ratio preceded the diagnosis of AD. This is yet 
another marker of interest that the APOE4 allele may deleteriously impact AD 
risk [38].  
Although the EFAD model is fairly new, a variety of studies have been 
published indicating that the combination of APOE4 and FAD mutations leads to 
AD through multiple mechanisms. However, mechanisms that originate from the 
gut impacting one’s risk of developing AD has recently become of intense 
interest. The APOE allele has actually been implicated to impact the gut 
microbiome. In fact, the APOE4 allele actually appears to be protective against 
diarrhea, enteric infections, and malnutrition in children in the developing world 
such as in Brazil [39]. While these effects may not be as much of an issue in first 
world countries such as the United States, the APOE4 allele may save the lives 
of children in developing countries such as Brazil. However, they will still be at 
an increased risk of dementia as they age. Further, studies in AD mouse models 
have found alterations in amyloid pathology. Indeed, APP/PS1 transgenic mice 
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demonstrated an increase in amyloid pathology and immune reactivity in the 
intestines compared to wild-type mice [40]. In another study using this same 
APP/PS1 transgenic mouse model, Harach et al. found that germ-free (GF) mice 
had decreased amyloid pathology in the brain compared to mice that did have a 
gut microbiome [41]. Based off of this, certainly the APOE allele and FAD 
mutations play a role in the gut microbiome, although much has yet to be 
learned.  
 
 
1.3 Gut Microbiome: Overview 
 
The gut microbiome, or the trillions of bacteria that inhabit our gut, play 
a profound and ever-growing role on the host’s health. The microbiome 
contains over 1,000 bacterial species, though it may actually be much higher 
than this, each exerting their own specific effects. However, there are just a 
few primary bacterial phyla: Firmicutes, Bacteroidetes, Actinobacteria, 
Verrucomicrobia, and Proteobacteria [42]. Interestingly, the ratio of Firmicutes 
to Bacteroidetes has become a well-known biomarker of certain diseases with 
an increased Firmicutes to Bacteroidetes ratio present in obesity. This may 
even lead to excessive low-grade inflammation [43]. Confusingly, in 
inflammatory bowel disease (IBD) patients, an increased and decreased 
Firmicutes to Bacteroidetes ratio has been observed [44, 45]. Importantly, this 
ratio is altered with age. Although not unanimous in the literature as diet and 
environment play a profound role, children typically have decreased amounts 
of Firmicutes, and thus a decreased Firmicutes to Bacteroidetes ratio, but this 
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increases dramatically as one enters into adulthood. However, after adulthood 
and into elderly status, a decreased Firmicutes to Bacteroidetes ratio is 
exhibited [46]. The mechanisms behind these changes are not currently well 
understood.     
Certain bacterial species have been demonstrated to have important 
effects on the host, beneficial and deleterious. For example, Akkermansia 
muciniphila has been demonstrated to increase insulin sensitivity but decrease 
fat mass and inflammation [47]. In contrast, other bacterial species such as 
Clostridium difficile, or C. diff, an opportunistic bacterium that when in excess, 
produces two exotoxins, A and B, can cause diarrhea. Elderly hospital patients 
are particularly susceptible and deaths are not uncommon [48]. Considering 
there are over 1,000 bacterial species, the aforementioned two bacterial 
species are just the tip of the iceberg and thus, more research needs to be 
conducted to elucidate the effects of each.   
The gut microbiota impacts host metabolism as demonstrated in germ-
free (GF) mice studies. In one GF mice study, the GF mice have decreased 
body fat compared to control mice despite eating more calories [49]. This is 
indicative of the gut microbiota impacting energy harvest from food and 
subsequent fat storage. GF mice are even protected from insulin resistance 
[50] but when the feces of control mice were inserted into germ-free mice, an 
increase in body fat and insulin resistance ensued [51]. This may partly be due 
to the differences in the development of the gut epithelium with control mice 
having more small intestinal villi, promoting increased energy harvest. Further, 
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alterations in gene expression in the liver and adipose tissue are present 
between GF and control mice, altering lipid and mitochondrial metabolism [52, 
53]. The alterations in fat storage may also be due to differential regulation of 
the intestinal expression of fasting-induced adipose factors (FIAF). FIAF 
inhibits lipoprotein lipase (LPL) in adipose tissue and activates the breakdown 
of triacylglycerol into fatty acids, used by muscle and adipose tissue. GF mice 
had elevated FIAF relative to control mice, leading to increased fat mass in 
control mice [51]. Similar studies have been performed in humans where fecal 
matter was transferred from lean donors to individuals with metabolic 
syndrome. One study found that the individuals with metabolic syndrome had 
increased microbial diversity and improved insulin sensitivity after the fecal 
donation [54]. Taken together, the gut microbiota regulates glucose and lipid 
metabolism while ultimately impacting fat mass and body weight.  
Next, the gut microbiota synthesizes metabolites that affect host 
metabolism. This includes short chain fatty acids (SCFAs) and bile acids, 
among others. SCFAs are used extensively as an energy source for colonic 
cells as well as a ligand for G-protein coupled receptors (GPR), including 
GPR41 and GPR43, in many different tissues. Activation of these GPRs may 
help reduce body weight and improve insulin sensitivity in liver and muscle [51, 
55]. One potential mechanism is increased secretion of anorexigenic 
hormones such as glucagon like peptide-1 (GLP-1) and peptide YY (PYY) via 
GPR signaling [56]. Indeed, these hormones are thought to beneficially impact 
 
 17 
glucose metabolism [57, 58] and by working in the hypothalamus, decrease 
appetite and thus, food intake [59].  
The gut microbiota influences bile acid metabolism and thus impacts the 
absorption of dietary lipids and fat-soluble vitamins. The primary bile acids 
include cholate (CA) and chenodeoxycholate (CDCA), which are synthesized 
in the liver. However, bile undergoes modifications before release into the 
intestines via conjugation by glycine or taurine, boosting their function. 
Although 95% of bile acid is reabsorbed by the ileum and returned to the liver, 
the rest is converted into secondary bile acids by the gut microbiota [60]. The 
secondary bile acids include deoxycholic acid (DCA) and lithocholic acid (LCA) 
and have been demonstrated to decrease weight gain and serum cholesterol 
[61]. In another study, taurine-conjugated DCA and CDCA were associated 
with insulin resistance in nondiabetic individuals [62]. Although not particularly 
well understood, bile acids may impact glucose metabolism through the 
nuclear farnesoid X receptor (FXR) [63], explored next.  
The production of bile acids is regulated by negative feedback inhibition 
via the FXR [64], which the gut microbiota impacts. Indeed, the gut microbiota 
has been demonstrated to cause diet-induced obesity via FXR signaling. 
Further, Parseus et al. found the microbiota to increase adipose tissue 
inflammation and hepatic expression of genes involved in lipid uptake [65]. It 
has also been demonstrated that treatment with an FXR agonist increased 
insulin sensitivity [66]. Interestingly, the activation of FXR by bile acids may 
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even impact the immune system via increased expression of inducible Nitric 
Oxide Synthase (iNOS) and IL-18 [67].  
The gut microbiota has a profound effect on the immune system. One 
reason is due to SCFAs activation of GPRs, namely GPR43, impacting the 
immune system by regulation of colonic regulatory T-cells [68]. They have also 
been demonstrated to increase IL-10, an anti-inflammatory cytokine [69], 
suppress NF-κB and IL-2, regulate neutrophils [70], and suppress cytokine 
production by monocytes [71]. Quite interestingly, SCFAs even impact the 
brain by decreasing BBB permeability [72] and by regulating microglia maturity 
[73]. However, the SCFAs are not the only metabolites produced by the gut 
microbiota that impact the immune system. Indeed, aromatic amino acids such 
as tryptophan can be metabolized to, for example, indole 3-propionic acid 
(IPA). IPA is metabolized by the microbial species Clostridium sporogenes [74] 
and can act as a ligand for the pregnane X receptor (PXR). Through PXR, IPA 
can induce an increase in junctional protein mRNA expression while 
decreasing TNF-α [74], leading the host to better intestinal health and 
decreased inflammation.  
Another way the gut microbiome interacts with the immune system is 
through lipopolysaccharide (LPS), an endotoxin from the outer cell membrane 
of Gram-negative bacteria, which can enter the circulation when a leaky gut is 
present in the host. Leaky gut is the increased permeability of the intestinal 
wall leading to low-grade inflammation and in extreme cases, sepsis [75]. 
Upon LPS entering the circulation, it can reach the liver or adipose tissue and 
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initiate an innate immune response. This response includes the activation of 
CD14 in the macrophage, activating toll-like receptor 4 (TLR4), which then 
activates NF-κB and activator protein 1 (AP-1)[76]. Furthermore, circulating 
endotoxin levels have also been linked to increased TNF-α and IL-6 in 
adipocytes [77]. Interestingly, this deleterious alteration in immune function 
may also lead to metabolic dysfunction. Indeed, Cani et al. demonstrated that 
continuous subcutaneous infusion of LPS in mice leads to hyperglycemia and 
insulinemia, weight gain, increased markers of inflammation, and liver insulin 
resistance [78]. Importantly, LPS has also been demonstrated to increase 
inflammation in the brain via activated microglia and increased expression of 
TNF-α, Monocyte Chemoattractant Protein (MCP-1), IL-1β, and NF-κB [79]. 
Clearly, the production of metabolites by the gut microbiome has a deep 
impact on the host immune system, even in the brain. 
 
1.4 Gut-Brain Axis  
 
The gut-brain axis (GBA) is the bi-directional communication between the 
gut and the brain. Although a fairly new development in research, a few methods 
of communication between the gut and brain have been identified. One such is 
through the SCFAs butyrate, acetate, and propionate, which are produced by 
certain bacterial species such as Bacteroides and Roseburia inulinivorans [80]. 
Specifically, butyrate has been demonstrated to prevent inflammatory responses 
via NFκB inhibition in murine N9 microglia, hippocampal slice cultures [81], and 
HT-29 cells [82]. Butyrate also affects BBB permeability [72] and along with 
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propionate, improves glucose sensitivity and body weight control via gut-brain 
neural circuits [83]. Further, excess acetate levels caused by an altered gut 
microbiota were demonstrated to lead to obesity via the microbiome-brain-β cell 
axis [84]. Another form of communication in the GBA is through tryptophan 
metabolites. One example is indole propionic acid (IPA), which has been 
demonstrated to inhibit Aβ fibril formation in neurons and neuroblastoma cells 
[85]. Another tryptophan metabolite is serotonin, a neurotransmitter in the brain 
and enteric nervous system (ENS). Interestingly, 95% of serotonin is produced 
by ENS neurons and gut mucosal enterochromaffin cells [86]. In the gut and 
periphery, serotonin impacts GI secretion and motility [87]. Additionally, the gut 
microbiota can communicate through neural pathways such as through the ENS 
and importantly, vagus nerve [88]. In fact, the vagus nerve appears, at least in 
part, to be responsible for central GABA receptor expression, anxiety and 
depression-like behavior, and corticosterone response [88]. In another study, the 
reduction of anxiety by the probiotic Bifidobacterium longum was absent in mice 
without a vagus nerve [89]. Next, numerous neurotransmitters that are produced 
by enteroendocrine cells (EECs) in the GI tract that are stimulated by gut 
microbial taxa or by-products thereof are also able to potentially impact the brain 
[90]. This includes peptide YY, neuropeptide Y (NPY), and cholecystokinin. 
Finally, another GBA communication pathway involves immune signaling [91]. 
Indeed, the gut microbiota is a very important immune organ that can impact the 
brain. Notably in this communication pathway, consumption of the probiotic 
Bifidobacterium infantis 35624 was found to enhance IL-10 in the periphery of 
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humans [92]. Meanwhile, when GF mice are given commensal bacteria, 
increases in Treg and IL-10 occur [93]. Importantly, it is thought that certain 
immune cells can generate neurotransmitters that can signal to the brain and 
even influence behavior [91]. An example of this in one study in mice found that 
Mycobacterium vaccae activated the peripheral immune system, which went on 
to stimulate serotonergic neurons of the dorsal raphe nucleus of mice, increasing 
serotonin metabolism [94]. The study further proposed this was an important part 
of mood regulation. Collectively, the GBA and its various communication 
pathways play a pivotal yet sparsely explored role in the health of an organism. 
We believe this may be an exciting venue of research with the goal of preventing 
neurological diseases such as AD.  
 
1.5 Prebiotics: Overview 
 
To beneficially modulate the gut microbiota, an individual could consume 
prebiotics. Prebiotics are the non-digestible portion of food that stimulates the 
growth of beneficial bacteria. Although the exact definition of prebiotics varies, 
Bindels et al. proposed this definition: “a non-digestible compound that, through 
its metabolization by microorganisms in the gut, modulates composition and/or 
activity of the gut microbiota [95].” For clarity, these classifications must be met 
for a compound to be considered a prebiotic: digested by gastric enzymes in the 
upper gastrointestinal (GI) tract, stimulate the growth of certain beneficial 
bacteria, and fermented in the colon to produce metabolites such as SCFAs. 
Specific prebiotics include resistant starch, oligosaccharides, and inulin. 
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Prebiotics are, in general, non-digestible carbohydrates, or fiber, found in foods 
such as fruits, vegetables, whole grains, and legumes. Whole foods typically 
contain a mixture of insoluble and soluble fiber. Insoluble fiber does not dissolve 
in water, is minimally fermented, but promotes regular bowel movements and 
prevents constipation. On the other hand, soluble fiber forms a gel in water, can 
be fermented into beneficial metabolites such as SCFAs, decreases cholesterol, 
and regulates blood glucose. However, the benefits of soluble and insoluble often 
overlap [96]. Different kinds of prebiotics include oligosaccharides, resistant 
starch, inulin, etc. that are fermented by beneficial bacteria into SCFAs and other 
metabolites, producing many of their advantageous effects. Other benefits 
include improved gut barrier function, reduced colonies of pathogenic bacteria, 
decreased risk of CVD, promotion of weight loss, beneficial modulation of the 
immune system, enhanced mineral absorption, promotion of regular bowel 
movements and intestinal health, cancer prevention, and reduced cholesterol 
[97]. Although literature on prebiotics in regard to the GBA is scarce, prebiotics 
have been demonstrated to elevate central BDNF, levels of which decrease 
according to AD severity [98], and N-methyl-D-aspartate receptor (NMDA) [99], 
but reduce waking cortisol levels in human subjects [100]. Collectively, prebiotics 
have a vast array of benefits to the host and are easy to consume, making it an 
ideal nutritional intervention in the fight against neurological disorders such as 
AD.  
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1.5.1 Inulin 
 
For our project, we will use the prebiotic inulin, a soluble dietary fiber and 
member of the fructans group, due to its well-documented ability to increase 
SCFA production and increase Bifidobacterium bacterial populations [101]. 
United States citizens ingest 1-4g of inulin-type fructans (ITFs) per day, 
considerably less than the 3-11g eaten by Europeans [102]. To be an ITF, a β-(2-
1)-fructosyl-fructose glycosidic bond anywhere from 2 to 60 units long must be 
present, giving inulin its ability to resist gastric enzymes in the upper GI, only to 
be later fermented in the colon [101]. Notably, only gastrointestinal side effects 
have been reported with inulin consumption including diarrhea, abdominal 
rumbling, bloating, cramping, and excess flatulence. However, these effects are 
generally seen in intakes greater than 40g per day, although individual variation 
exists. A daily dose of 2.5-10g per day in humans is recommended to promote a 
healthy gut microbiota [103].  
Inulin is derived from the chicory root but is also found in garlic, onions, 
artichoke, and in processed foods as a functional fiber. For food application, 
when adding inulin, health claims can be made on the product, potentially 
persuading consumers to eat the food for added health benefits. Inulin can also 
be used to replace fat or sugar as inulin can be processed to have a similar taste 
and/or texture [101].  
ITFs include inulin, oligofructose, fructooligosacchardies (FOS), and 
bifidogenic oligo- or polysaccharide chains. The latter of which are more derived, 
smaller molecules. A way to classify these types is by their degree of 
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polymerization (DP) [101]. For example, inulin has not undergone extensive 
processing and is generally greater than 10 DP. However, oligofructose is less 
than 10 DP and has undergone partial hydrolysis with all long chain ITFs 
removed. Finally, FOS are very short chain inulin type fructans that are produced 
from sucrose. Unfortunately, the literature can vary on classifying the types of 
inulin by DP, so one should be careful when looking to specifically identify ITFs. 
Further, the DP of ITFs also determines the location they will exert their effects. If 
the product has a lower DP, it will exert effects towards the proximal colon, while 
less derived, higher DP ITFs will exert effects in the distal colon. In the colon, 
these ITFs are fully metabolized into carbon dioxide, hydrogen, SCFAs, lactate, 
and other metabolites. This fermentation also makes the colon more acidic, 
thought to be advantageous for the growth of beneficial bacteria, along with 
increasing fecal content size. Finally, ITFs do indeed affect the gut microbiota. 
Although not entirely conclusive due to differences in the type of inulin used in 
the literature and individual differences, ITFs stimulate Bifidobacteria, increasing 
its bacterial biomass. Indeed, Bifidobacteria can consume non-digestible 
carbohydrates as energy sources such as ITFs. This genus contains at least 51 
different species that have numerous beneficial effects including production of B 
vitamins, maturation of immune system, protection of the gut barrier and 
pathogens, and production of SCFAs [104]. When examining the literature, one 
human study found that 20g of inulin was given for 8 days, and then ramped up 
to 40g a day for another 10 days. This dietary regimen produced significant 
increases in Bifidobacteria, whereas Enterococci and Enterobacteriaceae were 
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decreased. However, effects of ITFs on bacterial species other than 
Bifidobacteria are inconclusive at this time. In a recent study by Vandeputte et al. 
in human subjects, inulin was found to alter bacterial abundance at the genus-
level via increased Bifidobacterium and Anareostipes but decreased Bilophila 
[105]. Notably, some evidence supports a dose-dependent response to 
increasing levels of inulin intake although this may depend on the state of the 
host and variation in their gut microbiota prior to treatment with inulin [101].  
 Inulin is well known in the literature in both human and animal models and, 
despite some inconsistencies, has time and time again produced beneficial 
effects, making it quite possibly the most studied and verified of all prebiotics. 
Indeed, inulin has been suggested to help with constipation in elderly females by 
increasing stool frequency and making them softer [106], while other studies 
have not demonstrated notable effects [103]. Similarly, inulin has been 
demonstrated, albeit inconsistently, to reduce total cholesterol, LDL-cholesterol, 
VLDL-cholesterol, and triglycerides in dyslipidemic and obese subjects [107]. In a 
recent meta-analysis examining the effect of ITFs on blood lipids and glucose 
levels in humans that were healthy, dyslipidemic, obese, and T2D patients, ITFs 
were demonstrated to decrease LDL across all groups. However, ITFs 
decreased fasting insulin and increased HDL only in certain T2D subgroups. The 
authors attribute the latter to the differences in the gut microbiota and 
pathological state of the subjects, e.g. T2D patients have increased blood 
glucose and lipids. Nevertheless, this meta-analysis does provide compelling 
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evidence that ITFs can indeed beneficially impact blood lipid profiles and 
glucose.   
 In animal models, ITFs have also been demonstrated to have anti-
carcinogenic effects. Indeed, supplemented inulin has demonstrated anti-
carcinogenic effects in one study using mice and rats that were induced with 
colon cancer using azoxymethane and dextran sulfate sodium (AOM/DSS). In 
mice, the group fed the inulin-like fructans had decreased intestinal polyps and 
decreased markers of inflammation such as TNF-α. Even more interesting, the 
inulin groups had increased bone densitometry in their femur and vertebra in a 
separate cohort of rats. However, serum calcium levels were not different [108].  
Nevertheless, inulin has demonstrated anti-carcinogenic and anti-inflammatory 
effects in the colon. The inconsistencies in the literature may be due to amount of 
inulin given in each study.  
 Specific doses of inulin in animal models have varied but for the most part, 
show benefits. In one of the more extreme cases, Parnell et al. fed 8-week-old 
male lean and obese rats 0, 10%, or 20% of a 1:1 inulin and oligofructose mix for 
10 weeks. The primary finding of this study was that the prebiotic fed groups had 
decreased serum cholesterol and a reduction in liver triacylglyceride (TAG) 
buildup compared to the obese control rats. A dose-response effect was not 
observed but the authors suggest the 10% dose may be more beneficial. 
Notably, these effects were not seen in the lean mice [109]. Another study also 
used the 10% dose with an inulin fiber product called Orafti Synergy to test the 
ability of rats to absorb iron and magnesium after being exposed to omeprazole, 
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which inhibits passive magnesium transport and absorption. The results revealed 
that inulin was able to restore calcium transport in the omeprazole treated rats, 
but not magnesium, compared to the control group. As a side note, levels of 
butyrate in the cecum and colon were also increased compared to the control 
group [110]. Similar findings have been found in humans, with one study in 
young healthy men demonstrating inulin to increase calcium absorption and 
balance. However, the absorption of magnesium, iron, and zinc were not altered 
[111]. 
 In one study similar to the present dissertation project, Weitkunat et. al. 
looked at the effects of a 10% inulin and 10% cellulose diet in gnotobiotic 
C3H/HeOuJ mice colonized with a human microbiota, comprised of 8 
represented bacteria, for 6 weeks. Firstly, the cellulose diet had significantly 
greater fecal bulk and energy than the inulin group and thus, the inulin group had 
10% higher digestibility. However, the calculated energy assimilation was not 
different. This was apparent as the body weight and composition in the two 
groups was also not different. Nor was liver weight or epididymal white adipose 
tissue (eWAT). In regard to the gut microbiota, the inulin group had an increased 
total bacterial cell number due to the increase in 6 of the 8 members of their 
human gut microbiota. These included Anaerostipes caccae, Bacteroides 
thetaiotaomicron, Bifidobacterium longum, Blautia producta, Clostridium 
butyricum, and Clostridium ramosum. Importantly, the inulin group also had 
significantly increased amounts of the SCFAs acetate, propionate, and butyrate 
in the cecum and significantly increased acetate and propionate in the plasma of 
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the portal vein. Inulin also altered liver genes associated with lipogenesis and 
fatty acid elongation. Finally, the inulin group exhibited a decreased ratio of 
omega-6 to omega-3 in the plasma, liver, and eWAT. Together, the authors 
believe these results signify that inulin may alter and decrease hepatic lipid 
metabolism while the decreased omega-6 to omega-3 ratio may help decrease 
disease risk [112].  
Collectively, inulin and ITFs have demonstrated a large array of benefits in 
the literature; however, more research needs be conducted in order to 
understand the aforementioned inconsistencies. Further, very little research 
exists regarding inulin and the brain, an exciting area of future discoveries. 
  
1.6 Scope of Dissertation 
 
The overall objective of our project is to use the prebiotic inulin to 
modulate the gut microbiota, reducing the risk of developing Alzheimer’s disease 
(AD)-like symptoms. For all aims, we will use a mouse model of C57BL/6 
background that overexpresses human Aβ via 5 familial-AD (5xFAD) mutations 
and expresses either the knocked-in human APOE3 (E3FAD) or APOE4 
(E4FAD) gene. Notably, a prevention strategy can be utilized in these mice as 
this mouse model gives us a known timeline of when to treat the mice with the 
prebiotic inulin. Our central hypothesis is that the prebiotic inulin will restore 
metabolic function and reduce AD pathology, including Aβ and 
neuroinflammation, in asymptomatic E4FAD mice. Our rationale is that once we 
learn if manipulation of the gut microbiota with the prebiotic inulin can alter the 
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gut-brain axis and decrease AD risk factors, we can administer innovative 
treatments for its prevention. As such, we will test our central hypothesis by 
these three specific aims:   
Specific Aim 1. To identify the effects of the prebiotic inulin on the 
gut microbiota and induced metabolism changes thereof between E3FAD 
and E4FAD mice. This chapter will discuss the differences in the gut microbiota 
between E3FAD and E4FAD mice along with the effect of the prebiotic inulin on 
thereof compared to the control diet. Further, it will test for potential metabolites, 
such as the short chain fatty acids (SCFAs), generated by the gut microbiota with 
and without prebiotic treatment in the cecum and in fecal culture.   
Specific Aim 2. To identify the effects of the prebiotic inulin on 
metabolism in the periphery and central nervous system (CNS) between 
E3FAD and E4FAD mice. This chapter will discuss the effect of the prebiotic 
inulin on metabolism in blood plasma, in vivo brain, and brain tissue between 
E3FAD and E4FAD mice. Specifically, metabolites produced from the prebiotic 
inulin in the gut microbiota that may have an impact on the brain will be 
assessed.    
Specific Aim 3. To identify the effects of the prebiotic inulin on AD 
risk factors and pathology between E3FAD and E4FAD mice. This chapter 
will discuss if the impact of the prebiotic inulin can reach the brain and decrease 
AD risk factors, including CBF, inflammation, anxiety, and cognition, and Aβ 
aggregation in E3FAD and E4FAD mice and any differences seen between 
E3FAD and E4FAD mice.  
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Chapter 2 Methods and Materials 
  
2.1 Animals, Caging, and Diet Information 
 
 For all aims, the EFAD transgenic mouse model (E3FAD and E4FAD) was 
used. This C57BL/6 background mouse model is a cross between transgenic 
mice that overexpress Aβ via 5 familial-AD (5xFAD) mutations with transgenic 
mice that have either the target replacement human APOE3 or APOE4 allele. We 
determined the sample size (N = 15/group, Male:Female = 50/50) via power 
analysis to ensure comparison at a 0.05 level of significance and a 90% chance 
of detecting a true difference of each measured variable between groups. Each 
mouse was given its own cage housed in a specific pathogen-free facility in order 
to avoid the potential for hostility when combining unfamiliar mice into one cage. 
Further, mice were house independently for gut microbiome analysis due to the 
potential for microbiome transfer, e.g. mice eating each other’s feces giving them 
a very similar gut microbiome. Thus, the mice would be N = 1 for that particular 
cage. Individual housing will also help us avoid cage effects [113]. E3FAD and 
E4FAD mice were weighed biweekly, given ad libitum access to food and water, 
and fed either a prebiotic or vehicle control diet (detailed in Table 3.1) starting at 
3 months of age. Both the prebiotic and vehicle control diet are modifications of 
TestDiet’s AIN-93G Semi-Purified Diet 57W5. Experimental procedures, 
including magnetic resonance imaging and animal behavior tests, started when 
mice reached 7 months of age and after completion of these experiments, the 
mice were sacrificed with cecum weight measured and brain, blood, cecal 
contents, and intestinal tissue collected. All experimental procedures were 
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performed according to NIH guidelines and approved by the Institutional Animal 
Care and Use Committee (IACUC) at the University of Kentucky (UK). 
 
2.2 Fecal Bacterial Culture 
 
Fecal samples were collected from 7-month old E3FAD and E4FAD mice 
fed a standard chow diet and pooled together into their respective groups with 
175 mg per sample weighed. The samples were placed in an anaerobic chamber 
and transferred to a clean tube containing 1.5 ml media. The samples were 
mashed into a semi-suspension, sealed, and taken out of the chamber. Samples 
are centrifuged at 500 rpm for 5 minutes. A 10-cc syringe is used to pull 8 mLs of 
the supernatant into an anaerobic tube. Samples are centrifuged again at 3000 
rpm for 10 minutes. Next, the samples are aspirated and maintained in anaerobic 
conditions. The pellets are suspended in 9 mL media and separated into tubes. 
Next, either inulin (5g/L) or the control, glucose (5g/L) were added. The samples 
sit for either 24 or 48 hours with subsequent collection of 1 mL from each 
sample. The samples are centrifuged at 21,000 g for 2 minutes and supernatant 
collected. The samples can then be frozen until further analysis. All groups were 
run in triplicate.  
 
2.3 Gut Microbiome Analysis 
 
For fecal DNA amplification, fecal samples were collected from all mice 
per group (N = 15/group, M:F = 50/50). A DNeasy PowerSoil Kit (Qiagen, Hilden, 
Germany, Cat. No. 12888-100) was used for fecal DNA extraction, according to 
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the manufacturer’s protocol. Genomic DNA was PCR amplified with primers 
CS1_515F and CS2_926R [114] targeting the V4-V5 regions of microbial 16S 
rRNA genes using a two-stage “targeted amplicon sequencing (TAS)” protocol 
[115, 116]. First stage amplifications were performed with the following 
thermocycling conditions: 95˚C for 3 minutes, 28 cycles of 95˚C for 45 seconds, 
55˚C for 45 seconds, 72˚C for 90 seconds and final elongation at 72˚C for 10 
minutes. Barcoding was performed using a second-stage PCR amplification with 
Access Array Barcode Library for Illumina Sequencers (Fluidigm, South San 
Francisco, CA; Item# 100-4876). The pooled libraries, with a 15% phiX spike-in, 
were loaded on a MiSeq v3 flow cell, and sequenced using an Illumina MiSeq 
sequencer, with paired-end 300 base reads. Fluidigm sequencing primers, 
targeting the CS1 and CS2 linker regions, were used to initiate sequencing. De-
multiplexing of reads was performed on instrument. Second stage PCR 
amplification and library pooling were performed at the DNA Services (DNAS) 
facility within the Research Resources Center (RRC) at the University of Illinois 
at Chicago (UIC). Sequencing was performed at the W.M. Keck Center for 
Comparative and Functional Genomics at the University of Illinois at Urbana-
Champaign (UIUC). 
For microbial analysis, forward and reverse reads were merged using 
PEAR [117]. Primer sequences were identified using Smith-Watermann 
alignment and trimmed from the sequence. Reads that lacked either primer 
sequence were discarded.  Sequences were then trimmed based on quality 
scores using a modified Mott algorithm with a PHRED quality threshold of p = 
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0.01, and sequences shorter than 300 bases after trimming were discarded. 
QIIME v1.8 was used to generate operational taxonomic unit (OUT) tables and 
taxonomic summaries [118]. Briefly, the resulting sequence files were merged 
with sample information. OTU clusters were generated in a de novo manner 
using the UCLUST algorithm with a 97% similarity threshold [119]. Chimeric 
sequences were identified using the USEARCH61 algorithm with the 
GreenGenes 13_8 reference sequences [120]. Taxonomic annotations for each 
OTU were using the UCLUST algorithm and GreenGenes 13_8 reference with a 
minimum similarity threshold of 90% [119, 120]. Taxonomic and OTU abundance 
data were merged into a single OTU table and summaries of absolute 
abundances of taxa were generated for all phyla, classes, orders, families, 
genera, and species present in the dataset. The taxonomic summary tables were 
then rarefied to a depth of 10,000 counts per sample. 
Shannon and Bray-Curtis dissimilarity indices were calculated with default 
parameters in R using the vegan library [121, 122] and visualized as box plot and 
NMDS plot, respectively. Shannon index is used to calculate -diversity, or the 
species richness within a single habitat, via 𝐻 =  ∑ (𝑝𝑖 ∗ 𝑙𝑛 𝑝𝑖)𝑠𝑖=𝑙  where H = 
Shannon diversity index, pi = fraction of the entire population made up of species 
i, S = number of species, ln = natural logarithm, and  = sum of species. A higher 
H value indicates a more diverse community within a particular sample. Bray-
Curtis dissimilarity is used to calculate -diversity, the diversity of taxonomic 
abundance between difference samples, via 𝐵𝐶𝑖𝑗 = 1 −
2𝐶𝑖𝑗
𝑆𝑖+𝑆𝑗
  where i and j = the 
two sites, Si = total number of specimens on site i, Sj = total number of 
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specimens counted on site j, and Cij = sum of only lesser counts for each species 
in both sites. The rarefied genus data, taxonomic level 6, were used to calculate 
both indices.  Plots were generated in R using the ggplot2 library [123]. 
Significant differences among tested groups was determined using the Kruskal-
Wallis one-way analysis of variance and analysis of variance using distance 
matrices (ADONIS). The group significance tests were performed on the rarefied 
genus data, taxonomic level 6 (genus), using the group_significance.py script 
within the QIIME v1.8 package. 
 
2.4 Plasma Scyllo-Inositol 
 
A subset of 10 mice per group (N = 10, M:F = 50/50) was used for testing 
with a total of 50 ul mouse plasma mixed with 200 ul acetone, for a final 
concentration of 80%, to precipitate protein at -80C for 30 minutes. The 
precipitation was centrifuged out at 21000 g for 20 minutes at 4C. The 
supernatants were lyophilized overnight and reconstituted in D2O (> 99.9%, 
Cambridge Isotope Laboratories, MA) containing 0.1 mM EDTA 
(Ethylenediaminetetraacetic acid, Sigma Aldrich, St. Louis, MO) and 0.5 mM d6-
2,2-dimethyl-2-silapentane-5-sulfonate (DSS) (Cambridge Isotope Laboratories, 
Tewksbury, MA) as NMR internal standard. All NMR experiments including 1D 1H 
and 2D 1H HSQC were performed on an Agilent DD2 14.1 Tesla NMR 
spectrometer (Agilent Technologies, CA) equipped with a 3 mm inverse triple 
resonance HCN cryoprobe. All spectra were processed using MNova software 
(MestreLab, Spain). 1D 1H spectra were acquired with standard PRESAT pulse 
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sequence at 15 C with soft pulse pre-saturation on the HOD resonance 
frequency to suppress water signal. A total of 16,384 data points was acquired 
with 2 seconds acquisition time, 512 transients, 12 ppm spectral width, and 4 
seconds recycle delay time during which water peak was irradiated by soft pulse 
for suppression. The spectra were then linear predicted and zero filled to 128 k 
points and apodized with a 1 Hz exponential line broadening function. For 
quantification, the peak intensities were extracted using the peak-fitting 
deconvolution method provided by MNova software. The peak intensity of scyllo-
inositol resonant at 3.34 ppm were converted into nmoles by calibration against 
the peak intensity of internal standard DSS (with known quantify of 27.5 nmoles) 
at 0 ppm. 2D heteronuclear single quantum coherence (HSQC) were acquired to 
help confirm the peak assignments. The 2D HSQC spectra were recorded with 
13C adiabatic decoupling scheme for broad range decoupling during proton 
acquisition time of 0.25 seconds. 1,796 data points were collected each transient 
and a total of 16 transients were acquired with 12 ppm spectral width. A total of 
256 increments were collected in the carbon F1 dimension with a spectral width 
of 200 ppm. The HSQC spectra were linear predicted once and zero filled to 4 k 
data points in the F2 proton dimension and 1 k points in the F1 carbon 
dimension. The scyllo-inositol peak resonance was at 3.34 ppm in proton 
dimension and 70.3 ppm in carbon dimension. 
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2.5 Metabolomics Profiling 
  
For all aims, mouse blood, brain, and cecal contents were collected. The 
whole blood and brains were then sent to Metabolon (Durham, NC) for 
metabolomic profile (N = 8/group, M:F = 50/50). The cecal contents and whole 
blood were sent for SCFA analysis. For the metabolomic profiling, metabolon’s 
standard solvent extraction method was used to prepare the samples, which 
were then equally split for analysis via liquid chromatography/mass spectrometry 
(LC/MS) or gas chromatography/mass spectrometry (GC/MS) using their 
standard protocol [124]. 
For SCFA analysis in the whole blood (N = 8/group in ng/mL) and cecal 
contents (N = 8/group in g/g), 8 SCFAs were analyzed by LC-MS/MS. These 
were as follows: acetic acid (C2), propionic acid (C3), isobutyric acid (C4), 2-
methylbutyric acid (C5), isovaleric acid (C5), valeric acid (C5), and caproic acid 
(C6). Both sets of samples are stable labelled with internal standards and 
homogenized in an organic solvent. The samples are then centrifuged followed 
by an aliquot of the supernatant used to derivatize to form SCFA hydrazides. 
This reaction mixture is subsequently diluted, and an aliquot is injected into an 
Agilent 1290/AB Sciex QTrap 5500 LCMS/MS system. This system is equipped 
with a C18 reversed phase UHPLC column operated in negative mode using 
electrospray ionization (ESI). The raw data was analyzed by AB SCIEX software 
(Analyst 1.6.2) with reduction of the data done in Microsoft Excel 2013. Analysis 
was done in a 96-well plate with two calibration curves and 6-8 quality control 
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samples per bath. Samples were labeled BLOQ if they fell below the quantitation 
limit and ALOQ if they fell above the quantitation limit.  
For sample preparation of the rest of the samples, each sample was 
accessioned into a LIMS system, assigned a unique identifier, and stored at -70 
ºC. To remove protein, dissociate small molecules bound to protein or trapped in 
the precipitated protein matrix, and to recover chemically diverse metabolites, 
proteins were precipitated with methanol, with vigorous shaking for 2 minutes 
(Glen Mills Genogrinder 2000) as described previously [124, 125]. The resulting 
extract was divided into four fractions: one for analysis by ultra-high-performance 
liquid chromatography-tandem mass spectrometry run in positive mode (UPLC-
MS/MS+), one for analysis by UPLC-MS/MS run in negative mode (UPLC-
MS/MS-), one for analysis by gas chromatography–mass spectrometry (GC-MS), 
and one aliquot was retained for backup analysis, if needed.  
For mass spectrometry analysis, non-targeted UPLC-MS/MS and GC-MS 
analyses were performed at Metabolon, Inc. as described [124-126].  The 
UPLC/MS/MS portion of the platform incorporates a Waters Acquity UPLC 
system and a Thermo-Finnegan LTQ mass spectrometer, including an 
electrospray ionization (ESI) source and linear ion-trap (LIT) mass 
analyzer.  Aliquots of the vacuum-dried sample were reconstituted, one each in 
acidic or basic LC-compatible solvents containing 8 or more injection standards 
at fixed concentrations (to both ensure injection and chromatographic 
consistency).  Extracts were loaded onto columns (Waters UPLC BEH C18-2.1 x 
100 mm, 1.7 μm) and gradient-eluted with water and 95% methanol containing 
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0.1% formic acid (acidic extracts) or 6.5 mM ammonium bicarbonate (basic 
extracts).  The instrument was set to scan 99–1000 m/z and alternated between 
MS and MS/MS scans.    
Samples destined for analysis by GC-MS were dried under vacuum 
desiccation for a minimum of 18 h prior to being derivatized using 
bis(trimethylsilyl)trifluoroacetamide (BSTFA) as described [127]. Derivatized 
samples were separated on a 5% phenyldimethyl silicone column with helium as 
carrier gas and a temperature ramp from 60° to 340°C within a 17-minute period. 
All samples were analyzed on a Thermo-Finnigan Trace DSQ fast-scanning 
single-quadrupole MS operated at unit mass resolving power with electron 
impact ionization and a 50–750 atomic mass unit scan range.  The instrument is 
tuned and calibrated for mass resolution and mass accuracy daily. 
For quality control, all columns and reagents were purchased in bulk from 
a single lot to complete all related experiments. For monitoring of data quality 
and process variation, multiple replicates of extracts from a pool of human 
plasma were prepared in parallel and injected throughout the run, interspersed 
among the experimental samples. Instrument variability was determined by 
calculating the median relative standard deviation (RSD) for the standards that 
were added to each sample prior to injection into the mass spectrometers 
(median RSD = 4%; n = 21 standards). Overall process variability was 
determined by calculating the median RSD for all endogenous metabolites (i.e., 
non-instrument standards) present in 100% of technical replicate samples 
created from a homogeneous pool containing a small amount of all study 
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samples (median RSD = 6%; n = 170 metabolites). In addition, process blanks 
and other quality control samples are spaced evenly among the injections for 
each day, and all experimental samples are randomly distributed throughout 
each day’s run.  
For compound identification, quantification, and data curation, metabolites 
were identified by automated comparison of the ion features in the experimental 
samples to a reference library of chemical standard entries that included 
retention time, molecular weight (m/z), preferred adducts, and in-source 
fragments as well as associated MS spectra and curated by visual inspection for 
quality control using software developed at Metabolon [128]. Identification of 
known chemical entities was based on comparison to metabolomic library entries 
of more than 2,800 commercially-available purified standards. Subsequent 
quality control (QC) and curation processes were utilized to ensure accurate, 
consistent identification and to minimize system artifacts, mis-assignments, and 
background noise. Library matches for each compound were verified for each 
sample. Peaks were quantified using area under the curve. Raw area counts for 
each metabolite in each sample were normalized to correct for variation resulting 
from instrument inter-day tuning differences by the median value for each run-
day, therefore setting the medians to 1.0 for each run. This preserved variation 
between samples but allowed metabolites of widely different raw peak areas to 
be compared on a similar graphical scale.  Missing values were imputed with the 
observed minimum after normalization. For bioinformatics, the LIMS system 
encompasses sample accessioning, preparation, instrument analysis and 
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reporting, and advanced data analysis.  Additional informatics components 
include data extraction into a relational database and peak-identification 
software; proprietary data processing tools for QC and compound identification; 
and a collection of interpretation and visualization tools for use by data analysts. 
The hardware and software systems are built on a web-service platform utilizing 
Microsoft’s .NET technologies which run on high-performance application servers 
and fiber-channel storage arrays in clusters to provide active failover and load-
balancing.  
For metabolite quantification and data normalization, peaks were 
quantified using area-under-the-curve and a data normalization step for multiple 
day studies was utilized to correct any variance in instrument inter-day tuning 
differences. For one day studies, no normalization is necessary except for when 
accounting for an additional factor to account for any differences in metabolite 
levels due to differences in amount present in each sample. 
For statistical analysis, two types of statistical analyses were performed; 
significance tests and classification analysis. Statistical analysis is performed in 
ArrayStudio on log transformed data. For analyses not standard to ArrayStudio, 
either R or JMP are used. Multiple significance tests and classification methods 
are used. These include Welch’s two-sample t-test, Matched Pairs t-test, one-
way ANOVA, two-way ANOVA, and two-way repeated measures ANOVA. Also, 
correlation, and Hotelling’s T2 test were used. For statistical significance testing, 
p-values and q-values using False Discovery Rate (FDR) were utilized. Finally, 
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Random Forest, hierarchical clustering, and Principal Components Analysis 
(PCA) were used. 
  
2.6 Magnetic Resonance Imaging (MRI) 
  
All MRI experiments were performed on a 7T MR scanner (Clinscan, 
Bruker BioSpin, Germany) at the Magnetic Resonance Imaging & Spectroscopy 
Center at the UK. A subset of mice were randomly chosen from each group to 
undergo testing (N = 8-10/group). Mice were anesthetized with 4.0% isoflurane 
for induction and then maintained in a 1.2% isoflurane and air mixture using a 
nose cone. Respiration rate (50-80 breaths/minute) and rectal temperature (37 ± 
1 °C) were continuously monitored and maintained. T2-weighted structural 
images were acquired with field of view (FOV) =18 x18 mm2, matrix = 256 x 256; 
slice thickness = 1 mm, 10 slices, repetition time (TR) = 1500 ms, and echo time 
(TE) = 35 ms. Quantitative CBF (with units of mL/g per minute) was measured 
using MRI-based pseudo-continuous arterial spin labeling (pCASL) techniques 
[129]. A whole-body volume coil was used for transmission and a mouse brain 
surface coil was placed on top of the head for receiving. Paired control and label 
images were acquired in an interleaved fashion with a train of Hanning window-
shaped radiofrequency pulses of duration/spacing = 200/200 μs, flip angle = 25° 
and slice-selective gradient = 9 mT/m, and a labeling duration = 2100 ms [130]. 
The images were acquired by 2D multi-slice spin-echo echo planner imaging with 
FOV =18 x18 mm2, matrix =128 x 128, slice thickness = 1 mm, 10 slices, TR = 
4,000 ms, TE = 35 ms, and 120 repetitions. pCASL image analysis was 
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employed with in-house written codes in MATLAB (MathWorks, Natick, MA) to 
obtain quantitative CBF [131]. 
The next MRI technique used is magnetic resonance spectroscopy (MRS), 
or the measurement of metabolites in vivo [132]. MRS was being conducted in 
mouse brains, specifically in the hippocampus, with the following metabolites 
measured: alanine (Ala), total choline (TCho), glutamate-glutamine complex 
(Glx), myo-inositol (mI), lactate (Lac), NAA, phosphocreatine (PCr), total creatine 
(TCr), and taurine (Tau). These metabolites are plotted on a graph of signal 
intensity versus frequency. The following were used for a water-suppressed 
spectrum to test for these metabolites: TR = 1500 ms, TE = 135 ms, spectral 
width = 60 Hz, and average = 400. A voxel (2.0 mm x 5.0 mm x 1.3 mm) is 
placed over the bilateral hippocampus. Next, a non-water suppressed spectra is 
performed with 10 averages. Both of these spectra will be processed using the 
LCModel software to find the absolute concentration of the metabolites. To 
quantify the concentrations of the metabolites, the following equation was 
utilized: [m] = (Sm/Swater)[water]CnCav where [m] is the metabolite concentration, 
Sm is the metabolite intensity acquired from MRS, Swater is the water intensity 
acquired from MRS, [water] is the concentration of water (55.14mM at 310K), Cn 
is the correction for the number of equivalent nuclei for each resonance, and Cav 
is the correction for the number of averages [133]. 
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2.7 Amyloid-β Staining 
 
Mouse brains were collected (N = 5/group, M:F = 50/50) upon sacrifice and 
immediately put into 10% neutral buffered formalin for 24-48 hours. After this 
time period, the brains were transferred into 90% ethanol. Next, the brains were 
sent to the COCVD Pathology Research Core at the University of Kentucky to be 
embedded and sectioned onto microscope slides for immunohistochemistry. The 
sectioned tissue undergoes rehydration followed by tissue pretreatment in 90% 
formic acid for 3 minutes. The tissue was then treated with 3% H2O2 and 10% 
methanol for 30 minutes. Next, a M.O.M. Kit (Vector Laboratories, Inc. 
Burlingame, CA) was used following the standard protocol. A was identified 
using an anti-A1-17 mouse monoclonal 6E10 antibody (1:3000; Signet 
Laboratories, Dedham, MA). Following this portion of the protocol, a DAB 
substrate kit (also Vector Laboratories, Burlingame, CA) was used for 
visualization. Next, a background stain utilizing NISSL was completed followed 
by dehydration. The slides were next imaged on the Aperio ScanScope XT 
Digital Slide Scanner System in the University of Kentucky Alzheimer’s Disease 
Center Neuropathology Core Laboratory (20x magnificantion) and uploaded to 
the online database. Aperio ImageScope (version 12.3.2.8013) was used to 
analyze total anti-A counted at 20x magnification (0.495px/um). 10 boxes (ROIs 
that are 600x600x600 microns) were randomly placed in each sample image and 
counted for percent positive A (number of positive + number of strong 
positive/total number).  
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2.8 NanoString Array 
 
For RNA isolation and quantification, dissected hippocampus was 
processed for RNA isolation following manufacturer’s protocol (N = 5/group, all 
male) (Qiagen RNeasy Plus #74136). Quality and concentration of eluted RNA 
was measured by Nanodrop. 200ng of total RNA per sample was quantified 
using a NanoString array that consisted of 561 gene targets (Mouse Immunology 
v2 CodeSet). Following quality and housekeeping control normalization, there 
were a total of 318 genes that were above the background threshold.  
 
2.9  Animal Behavior Tests 
 
 All behavior tests were conducted over a two-week period with each test 
starting at the same time each morning (N = 7-9/group, M:F = 50/50). For each 
mouse, Elevated Plus Maze (EPM) was done first immediately followed by the 
Open Field Test and the Novel Object Recognition (NOR) test the next day. 
Radial Arm Water Maze (RAWM) testing was then carried out starting the day 
after NOR. All tests were carried out in the Rodent Behavior Center at the 
University of Kentucky.  
For elevated plus maze, all mice underwent three behavior tests. The first 
test is the EPM. We used the EPM to evaluate anxiety of the mice [129, 134]. 
The EPM consists of two open and two closed arms elevated 100 cm above the 
floor. Closed arms are perceived as safe zones, and thus mice with higher 
anxiety had tendency to stay in the closed arms. We determined the anxiety-
related behavior by measuring the time spent in the closed arms over the 1-
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minute test session by EthoVision XT 8.0 video tracking software (Noldus 
Information Technology). 
 For the open field test (OF), activity was recorded with EthoVision XT 8.0 
video tracking software (Noldus Information Technology). Each chamber was 
divided into a central and peripheral zone with the peripheral zone being next to 
the walls of the chamber. Data was collected for 15 minutes with edge duration 
being the amount of time the mice spent in the peripheral zone. This test is 
designed to assess anxiety-like behavior in the mice in response to a new, novel 
environment [135].  
For novel object recognition (NOR), the second behavioral test, used to 
test spatial recognition memory [136]. This task of recognition memory utilizes 
the fact that animals will spend more time exploring a novel object compared to 
an object that they are familiar with in order to satisfy their innate 
curiosity/exploratory instinct. Mice were given 10 minutes to explore two of the 
same objects in the “A/A” session. For the 10-minute “A/B” test session, one of 
the A objects was replaced by a novel object (B). There was a 2-hour delay 
between the A/A and A/B sessions. The total time mice spend investigating the 
objects was recorded and scored by the fully automated EthoVision XT 8.0 video 
tracking software (Noldus Information Technology). The D2 discrimination index 
was calculated by: D2 = (TB-TA) ÷ (TB +TA), where TB is the time spent with the 
novel object B, and TA is the time spent with the familiar object A. 
 The final test is radial arm water maze (RAWM), used to measure both 
spatial working memory and spatial reference memory [129, 137, 138]. The 
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RAWM task was conducted as described previously [133], following a 2-day 
testing paradigm. A staggered training schedule was used, running the mice in 
cohorts of ten mice, while alternating the different cohorts through the trials over 
day 1 and day 2 of the test. This alternating protocol was used to avoid the 
learning limitations imposed by massed sequential trials and to avoid fatigue that 
may result from consecutive trials. Day 1 is the “learning” phase where mice went 
through three blocks (Blocks 1-3; 5 trials in each block) to test learning and short-
term spatial memory. Day 2 is the “recall” phase where mice went through three 
additional blocks (Blocks 4-6) to test long-term memory after a 24-hour retention 
period to locate the platform. It is expected that after the two-day training, the 
mouse with intact memory can find the platform with minimal errors. Geometric 
extra-maze visual cues were fixed throughout the study on three sides of the 
curtains. Visual platform trials were included in the training and were used to 
determine if visual impairment could be a cofounding variable. Mouse 
performance was recorded by EthoVision XT 8.0 video tracking software (Noldus 
Information Technology) data analyzed by the EthoVision software for the 
number of incorrect arm entries, which are defined as errors. The video was 
reviewed for each mouse to ensure that the mice did not employ non-spatial 
strategies, such as chaining, to solve the task. 
 
2.10 Statistical Analysis 
 
All statistical analyses were completed using GraphPad Prism (GraphPad, 
San Diego, CA, USA). For all chapters, two-sample t-test and 2-way ANOVA was 
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performed for determination of differences between groups along with Tukey’s 
multiple comparisons test. For Metabolon, log transformations were conducted 
followed by ANOVA for identification of biochemicals that were significantly 
different between groups. Between group differences were assessed using p-
value and q-value, or false discovery rate. For the NanoString Array analysis, 
data are plotted as the mean ratio expression with their respective adjusted p-
value (Benjamini-Hochberg corrected). Further, 2-way ANOVA was used along 
with Sidak posthoc multiple comparisons correction for the individual genes.   
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Chapter 3 Specific Aim 1: To identify the effects of the prebiotic inulin on 
the gut microbiota and induced metabolism changes thereof between 
E3FAD and E4FAD mice. 
 
3.1 Summary 
 
 The gut microbiota plays a profound role on the host and recently, this has 
been found true in the brain and in neurological diseases such as AD. The 
differences between the gut microbiota and effects of consuming the prebiotic 
inulin on APOE3 and APOE4 carriers is unknown. PURPOSE: The purpose of 
this aim to identify the effects of the prebiotic inulin on the gut microbiota and 
induced metabolism changes thereof between E3FAD and E4FAD mice. 
RESULTS: Firstly, mice bodyweight and food intake were not changed due to the 
prebiotic diet, however, E3FAD and E4FAD mice fed the prebiotic inulin had a 
significantly larger cecum than control fed mice. In the cecal contents, both 
E3FAD and E4FAD fed the prebiotic inulin had significantly increased SCFAs but 
decreased isobutyrate. Next, our fecal culture experiment found an increase in 
scyllo-inositol in the inulin cultures compared to controls. In both the cecal 
contents and fecal culture, the E3FAD mice had a larger production of the 
aforementioned metabolites compared to the E4FAD mice. Further, the prebiotic 
inulin fed E3FAD mice altered the gut microbiota via decreased -diversity, 
significantly different -diversity, and increased beneficial and SCFA producing 
taxa, and decreased deleterious bacterial taxa. The E4FAD mice fed the 
prebiotic inulin saw more modest differences compared to the control fed mice 
with the gut microbiota showcasing a significantly different -diversity, but not -
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diversity, and also increased levels of beneficial taxa at the genus level. 
However, there were no differences due to the FAD mutations. CONCLUSIONS: 
To conclude, the prebiotic inulin beneficially impacted the host through increased 
production of beneficial metabolites such as the SCFAs and scyllo-inositol along 
with increasing beneficial taxa and decreasing deleterious taxa However, the 
E3FAD mice and E4FAD mice fed the prebiotic inulin showcased variation in the 
aforementioned outcomes as E3FAD mice appeared to gain more benefit due to 
the prebiotic inulin than did the E4FAD mice. Due to this, we believe prebiotics 
can be a beneficial and translatable nutritional intervention to improve gut health 
but taking genetics into account is highly warranted.  
 
3.2 Introduction 
 
The gut microbiota, or the trillions of bacteria in our gut, play a profound 
role on our health [42]. Indeed, the gut microbiota has been demonstrated to 
beneficially impact the host a variety of ways including through the immune 
system [139]. Recently, the bi-directional communication between the gut and 
the brain, or gut-brain axis (GBA), has become a topic of intense investigation 
[140]. Indeed, it appears the gut microbiota plays a role in anxiety and 
depression [141], and in other neurological disorders such as AD [142]. Recent 
work has found that AD patients have a distinct gut microbiota compared to 
controls [143] with alterations also seen in an AD mouse model [144]. Further, 
Harach et al. found that in an AD mouse model, the germ-free mice had less 
amyloid pathology than those that actually had a gut microbiota [41]. It is worth 
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noting that studies by Oria et al. have found human APOE4 carriers to have 
protection from diarrhea in early childhood, providing a survival advantage [39]. 
Further, in favela children in Northeast Brazil, this group found that APOE4 was 
protective against cognitive deficits due to enteric infections and diarrhea [145]. 
Due to this, we believe that our E3FAD and E4FAD mice will show a vastly 
different response to the prebiotic inulin and metabolites produced but in both, 
beneficial modulation of the gut microbiota by the prebiotic inulin could help 
prevent AD-like symptoms.  
Using prebiotics such as inulin may be used as a preventative measure in 
combating AD. Indeed, prebiotics are, as stated by one source, “a selectively 
fermented ingredient that allows specific changes, both in the composition and/or 
activity in the gastrointestinal microflora that confers benefits upon host well-
being and health [146].” Prebiotics must resist upper gastrointestinal (GI) 
enzymes, be fermented in the lower GI, and selectively stimulate the growth of 
beneficial bacteria [147]. Further, during the fermentation of prebiotics, beneficial 
metabolites are produced such as the short chain fatty acids (SCFAs) butyrate, 
acetate, and propionate, demonstrated to beneficially impact the brain [148, 149]. 
The prebiotic chosen for this project is inulin, derived from chicory root, but also 
found in other vegetables, fruits, and grains. Inulin is quite possibly the most well 
studied prebiotic and is well known for its numerous beneficial properties 
including increased mineral absorption, decreased inflammatory bowel syndrome 
(IBS) scores, and reduced cholesterol [101, 103]. Further, the prebiotic inulin has 
been demonstrated to increase the size of the cecum, which is thought to 
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indicate increased fermentation of beneficial metabolites and microbial content 
[150, 151]. We believe that using the prebiotic inulin to beneficially modulate the 
gut microbiota in E3FAD and E4FAD mice will lead to a change in metabolism 
via an increase in the fermentation of beneficial metabolites that could potentially 
help prevent AD pathology.  
The objective of this aim was to identify the effect of the prebiotic inulin 
and changes in the metabolism thereof between E3FAD and E4FAD mice. We 
hypothesized that the prebiotic inulin will beneficially modulate the gut microbiota 
and increase metabolite production in E3FAD and E4FAD mice. Specifically, we 
examined the body weight, food intake, and cecum weight of the mice along with 
an examination of the gut microbiota and its taxonomy in 16S rRNA sequencing 
and metabolites produced in the cecal contents and in fecal bacterial culture.  
 
3.3 Results 
 
3.3.1 Body Weight and Food Intake 
Table 3.1 demonstrates the diet composition of the prebiotic and vehicle 
control diets with the prebiotic diet containing 8% fiber from inulin and the vehicle 
control diet containing 8% fiber from cellulose. E3FAD and E4FAD were fed 
either the prebiotic or control diet for 4-months beginning at 3-months of age. To 
ensure the prebiotic diet did not alter bodyweight and food intake in the mice, 
bodyweight and food intake were measured biweekly and compared between 
groups. E3FAD and E4FAD mice that were fed the prebiotic diet saw no 
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significant differences in body weight (Fig. 3.1a) or food intake (Fig. 3.1b) 
compared to control fed mice.  
 
3.3.2 Cecum Weight and Cecal Metabolites 
 
The cecum, with cecal contents intact, was weighed upon sacrifice when 
the mice were around 7-months of age. The cecal contents of the mice were then 
collected and sent to Metabolon (Durham, NC) for metabolomics profiling via LC-
MS/MS. Due to the increased fermentation potential of the prebiotic inulin, we 
expected a change in cecum size between prebiotic and control fed mice. 
Indeed, mice that were fed the prebiotic inulin saw a drastically significant 
increase in cecum size compared to control fed mice in both E3FAD and E4FAD 
mice with an even greater increase seen in the E3FAD mice. Thus, we believed 
cecal metabolite production may vary between groups with mice fed the prebiotic 
inulin seeing more production. Indeed, both E3FAD and E4FAD mice fed the 
prebiotic inulin saw a significant increase in butyrate (Fig. 3.3b), acetate (Fig. 
3.3c), and propionate (Fig. 3.3d) but a decrease in isobutyrate (Fig. 3.3e). 
Further, the E3FAD mice saw a significantly greater increase in cecal propionate 
compared to the E4FAD mice fed the prebiotic inulin. The full results of short 
chain fatty acids is in Table 3.2. Overall, these results indicate that the prebiotic 
inulin causes an increase in fermentation in the cecum leading to a larger cecum 
and more beneficial metabolite production with an even greater increase seen in 
E3FAD mice, perhaps due to bacterial composition of E3FAD mice better able to 
produce SCFAs.   
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3.3.3 Scyllo-Inositol in Fecal Bacterial Culture 
 
To confirm that scyllo-inositol is indeed formed from gut microbiota 
bacteria, fecal samples from 7-month old E3FAD and E4FAD mice on a standard 
chow diet were collected and pooled into their respective groups and fecal cell 
suspensions were made under anaerobic conditions. The samples were given 
either inulin or a control, glucose, for 24 or 48 hours at which point the 
supernatant was collected and measured for scyllo-inositol via NMR. When inulin 
was added, scyllo-inositol formation was increased compared to the cultures that 
were only given glucose in both E3FAD and E4FAD mice, albeit only significantly 
in the E3FAD mice (Fig. 3.2a). However, the E3FAD fecal culture saw a much 
greater increase in scyllo-inositol compared to the E4FAD fecal culture (Fig. 
3.2a). These results indicate that the prebiotic inulin does indeed increase scyllo-
inositol formation in the gut microbiota in both E3FAD and E4FAD mice. Whether 
this change is due to inulin increasing proliferation of scyllo-inositol creating 
bacterial taxa or for other reasons remains to be determined. Further, E3FAD 
and E4FAD appear to have a different gut microbiota that impacts levels of 
scyllo-inositol production, a consideration that needs to be given to future studies 
and for carriers of these specific alleles.  
 
3.3.4 Gut Microbiota Diversity and Taxonomy 
 
To determine the differences in the gut microbiota between groups fed the 
prebiotic and control diet along with differences in E3FAD and E4FAD mice, fecal 
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samples were collected from each mouse upon reaching 7-months of age 
followed by DNA extraction and amplification. The DNA was then utilized for 16S 
rRNA sequencing and subsequent diversity and taxonomy analysis. For gut 
microbiota analysis in E3FAD mice, -diversity, a measure of the diversity within 
a sample by measuring the richness and evenness of that sample, was 
measured via the Shannon Diversity Index, H value, for fecal microbial 
communities at the genus taxonomic level. A higher H value indicates a more 
diverse community within that particular sample. A significant decrease was seen 
in E3FAD mice fed the prebiotic inulin compared to the control group (Gausian 
link function results, p < 0.0001) (Fig. 3.4a). Next, -diversity, a measure of the 
diversity of taxonomic abundance between different samples, was measured via 
the Bray-Curtis dissimilarity index at the genus taxonomic level. E3FAD mice fed 
the prebiotic inulin saw a significant difference in -diversity compared to the 
controls (Fig. 3.4b) (ANOSIM R statistic = 0.877, p-value = 0.001). For E4FAD 
mice, no difference was seen in -diversity (Gausian link function results, p = 
0.418) (Fig. 3.4c) but a significant difference was observed in -diversity 
(ANOSIM R statistic = 0.454, p-value = 0.001) (Fig. 3.4d). Significant changes in 
taxa were observed in numerous bacterial taxa due to the prebiotic inulin. In 
E3FAD mice fed the prebiotic inulin compared to the controls, a significant 
increase was seen in notable taxa at the genus level such as Bifidobacterium, 
Lactobacillus, Escheridia, Allobaculum, and Prevotella (Table 3.2). Moderate 
increases were seen in Akkermansia and Mucispirillum. In contrast, Bacteroides, 
Turicbacter, rc4-4, Oscillospira, and Dehalobacterium were decreased. At the 
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phylum level, Tenericutes were decreased in E3FAD mice fed the prebiotic inulin 
while Actinobacteria was increased. In E4FAD mice fed the prebiotic inulin at the 
genus level, notable taxa were increased such as Prevotella, Lactobacillus, and 
Mucispirillum. In contrast, Akkermansia, Escheridia, Parabacteroides, Turibacter, 
SMB53, AF12, and Dehalobacterium were decreased. No significant changes 
were present at the phylum level. There were also no notably significant 
differences due to the FAD mutations (Genotype). These results indicate that the 
prebiotic inulin alters the gut microbiota in E3FAD and E4FAD mice in, what we 
believe, a beneficial manner, despite a decrease in α-diversity in the E3FAD 
mice, but by increasing beneficial taxa. However, it appears the fermentation 
capabilities of E3FAD and E4FAD mice differ and this impacts the number of 
beneficial metabolites produced.  
 
3.4 Discussion  
 
Firstly, we see that the prebiotic inulin, 8% fiber from inulin, does not 
impact food intake and bodyweight in our mice compared to our control mice, 8% 
fiber from cellulose. Other studies have found similar results [152]. It is notable 
that inulin contains more kcal/g than cellulose, but the extra kcal/g may be 
consumed by the gut bacteria during fermentation. Nonetheless, this data helps 
us be rid of potential confounding factors that may be due to changes in body 
weight.   
Our work found that feeding the prebiotic inulin increased cecum size in 
our mice, especially so in E3FAD mice. Previous studies using the prebiotic inulin 
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have also found increases in cecum size [152, 153]. This is likely due to the 
cecum being the primary site of inulin fermentation [150, 151]. Kuo et al. also 
postulated that this may also indicate increased microbial content [152]. We 
believe this increase in fermentation may lead to increased production of 
beneficial metabolites, which is precisely what we saw with the SCFAs acetate, 
butyrate, and propionate. Interestingly, propionate was even more significantly 
increased in the E3FAD group fed the prebiotic inulin compared to the E4FAD 
group fed the prebiotic inulin. However, isobutyrate was decreased in the E3FAD 
and E4FAD mice fed the prebiotic inulin compared to their respective controls for 
unknown reasons likely related to bacterial SCFA metabolism. Nonetheless, the 
dramatic increase in SCFAs due to the prebiotic inulin does indeed confirm other 
studies that inulin increases SCFA levels [112, 154]. Whether the increased 
levels of SCFAs reached the periphery will be explored in the next chapter.  
Next, we demonstrate with our fecal culture experiment that the prebiotic 
inulin can increase scyllo-inositol production in the fecal microbiota. We can 
confirm that the production of scyllo-inositol does indeed come from the gut 
microbiota due to inulin feeding but we are unsure how exactly this occurs. To 
our knowledge, only one particular bacterial species has been identified to 
produce scyllo-inositol, Bacillus subtilis [155]. This taxon appears to produce 
scyllo-inositol from myo-inositol, the more common stereoisomer of scyllo-inositol 
found in foods such as fruits, beans, and nuts [156]. However, we do not 
understand why the taxon would generate the metabolite from myo-inositol or 
excrete the metabolite as opposed to using it as a carbon source. We also did 
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not see this bacterial species in our gut microbiota data. Nevertheless, we 
suspect that numerous other bacterial taxa increase scyllo-inositol production 
due to the prebiotic inulin as it is stimulating the growth of certain bacterial taxa 
that can produce this metabolite, increasing its production compared to the 
control. Interestingly, a study in inulin fed rats found that scyllo-inositol levels 
were dramatically increased in the myocardium and testes, although the reasons 
why were not understood [157]. It would appear that scyllo-inositol could be 
increased in numerous organs, not just the brain. Interestingly, our results 
demonstrate that the fecal microbiota of the E3FAD mice given inulin were able 
to produce much more scyllo-inositol at the 24- and 48-hour time points than the 
E4FAD mice given either inulin or the control. In fact, the E4FAD mice given 
inulin only saw an insignificant increase in scyllo-inositol at the 48-hour mark but 
at still considerably lower amounts than the E3FAD mice given the inulin at either 
timepoint. This indicates, similar to what we saw with the SCFAs of the cecal 
contents, that E3FAD mice are able to produce more beneficial metabolites than 
the E4FAD mice, probably due to better fermentation capacity. Thus, future work 
on identifying which bacterial taxa produce this and other metabolites and why 
the amounts may vary should be taken into consideration as these metabolites 
could potentially impact the brain and other organs in a therapeutic manner.  
Although research on scyllo-inositol is fairly scarce, some studies have 
demonstrated that scyllo-inositol in the brain is the highest source in the body 
[158] as it can pass through the blood brain barrier [159]. In fact, it increases in 
the brain as we age [160], may beneficially impact GLUT4 translocation in 
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muscle [161], and that it could be disturbed in certain disease states such as in 
chronic alcoholism [162] and even AD [163]. Indeed, scyllo-inositol has been 
demonstrated to inhibit Aβ aggregation in in vivo and in vitro trials [159, 164-167]. 
It is still not particularly understood how exactly the metabolite inhibits the 
aggregation of Aβ, but it is thought it may cap off a plaque and inhibit further 
aggregation and growth. However, it does not appear to break the plaques up 
[168]. This would indicate that scyllo-inositol would work best as a preventative 
measure before plaques have already or just recently formed. When comparing 
scyllo-inositol to its much more common and ubiquitous stereoisomer form myo-
inositol, scyllo-inositol proved to be more effective at inhibiting Aβ in an AD 
mouse model. In this study by McLaurin et al., they demonstrated that not only 
did their transgenic AD mice have a decrease in soluble and insoluble Aβ due to 
scyllo-inositol treatment, but they also had amelioration of memory deficits and a 
decrease in neuroinflammation, likely a consequence of Aβ inhibition [165]. 
Further in this study, they found that treatment in both younger, disease-free 
mice along with older mice with AD pathology, both saw significant benefits. In 
humans, clinical trials using scyllo-inositol as an orally administered fast track 
designation have been conducted. Unfortunately, in mild to moderate AD 
patients, the high dose scyllo-inositol (1000mg and 2000mg) groups saw 
increased kidney issues and thus, were discontinued. The lower dose group 
(250mg) did see a significant increase in brain ventricular volume and cerebral 
spinal fluid Aβ-42 but overall, the trial did not find significance in the primary 
clinical outcome [169].  
 
 59 
In the gut microbiome, many significant differences were seen. Typically, 
an increased α-diversity is thought to be beneficial [170], however, in our study 
we found that the prebiotic fed mice had a decrease in α-diversity compared to 
controls. Previous work by our lab and others have also found a decrease in 
diversity with improvements in other outcomes [171-173]. This may indicate that 
the prebiotic inulin stimulates the growth of only certain beneficial taxa, 
decreasing diversity and deleterious taxa, but overall, still increasing the health of 
the gut microbiota. We believe this to be the case in the E3FAD mice as the 
prebiotic inulin did indeed decrease α-diversity compared to the control mice 
although the E4FAD mice did not see as significant a difference. Further, both 
E3FAD and E4FAD saw a significant difference in -diversity, indicative of the 
powerful impact the prebiotic inulin has on the gut microbiota.  
Next, we explored the differences in bacterial taxa that the prebiotic inulin 
made in both E3FAD and E4FAD mice. We found that E3FAD mice fed the 
prebiotic inulin demonstrated a significant increase in taxa at the genus level 
such as Bifidobacterium, Lactobacillus, Escheridia, Allobaculum, and Prevotella 
compared to controls. In contrast, Bacteroides, Turicibacter, rc4-4, Oscillospira, 
and Dehalobacterium were decreased. Interestingly, the prebiotic inulin 
increased both Bifidobacterium and Lactobacillus. Due to inulin being a prebiotic, 
it is expected that Bifidobacterium and perhaps even Lactobacillus would be 
increased, both of which are fairly well studied and benefit the host through 
immunomodulation and emotional behavior, among other things [88, 174]. 
Meanwhile, Prevotella seems to proliferate on complex carbohydrates such as 
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inulin and has even been associated with improved glucose metabolism in a 
study using barley kernels, a dietary fiber [175]. One notable bacterial genera 
that was decreased was Bacteroides, a taxa that appears to act as both 
commensal and virulent, perhaps depending on the amount present [176]. At the 
phylum level, Tenericutes were decreased in E3FAD mice fed the prebiotic inulin 
while Actinobacteria was increased. One study has also found a decrease in 
Tenericutes due to inulin although the impact of this phylum is not well 
understood [177]. Further, the Actinobacteria phylum was also found to be 
moderately increased in this same study but has been previously associated with 
obesity [178]. Notably, this phylum does house the genus Bifidobacterium. Oddly, 
the E4FAD mice found no such changes in phylum level. However, the E4FAD 
mice fed the prebiotic inulin did show many differences at the genus level. 
Notable taxa that were increased included Prevotella, Lactobacillus, and 
Mucispirillum, all also increased in the E3FAD mice as well. In contrast, 
Akkermansia, Escheridia, Parabacteroides, Turibacter, SMB53, AF12, and 
Dehalobacterium were decreased in the E4FAD mice. Akkermansia is a 
beneficial taxa with numerous known benefits [179], the decrease shown here 
would be seen as a negative consequence especially as the E3FAD mice 
actually saw a moderate increase in Akkermansia. Bifidobacterium was also not 
increased in the E4FAD mice, another negative consequence. Further, SMB53 
has been decreased by fermentation in one study using prebiotics [180] while 
little is known about the other decreased taxa. Collectively, although there were 
similarities in taxa that the prebiotic inulin was able to increase and decrease 
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between E3FAD and E4FAD mice, there were also many differences, particularly 
in Akkermansia and Bifidobacterium, leading us to believe that genetic factors 
may indeed impact the gut microbiota and how the host responds to the 
presence of a beneficial prebiotic such as inulin. However, it is also worth noting 
that many of the significantly different taxa in our project have little information 
associated to them, a limitation of all gut microbiota research as we have much 
to learn on this topic and their impact on the host. Surprisingly, we did not see 
any differences in the gut microbiota due to the FAD mutations despite literature 
suggesting there may be differences [41].  
Altogether, the prebiotic inulin was able to increase cecum size and the 
fermentation of beneficial metabolites such as SCFAs and scyllo-inositol with the 
latter produced by the fecal microbiota, demonstrating that the fecal microbiota is 
indeed able to produce this metabolite. The prebiotic inulin also leads to 
beneficial modulation of the gut microbiota as evidenced by the increased 
number of beneficial taxa present. Interestingly, the E3FAD mice had a larger 
cecum, produced more beneficial metabolites, and appeared to gain more benefit 
in the gut microbiota compared to E4FAD mice. As far as we know, this is the 
first time that genetic differences have been shown to impact cecum size, 
metabolite production, and the response to the prebiotic inulin. Whether these 
beneficial outcomes by the prebiotic inulin are able to reach and benefit the 
periphery and brain will be explored in subsequent chapters.   
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Table 3-1 Diet composition  
Diet Prebiotic Diet Vehicle Control Diet 
Protein % 18.2 18.2 
Carbohydrate % 67.8 60.2 
Fat % 7.1 7.1 
Fiber % 8.0 (Inulin) 8.0 (Cellulose) 
Energy (kcal/g) 4.08 3.78 
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Table 3-1 Diet composition 
 The diet composition of the prebiotic and vehicle control diet. The prebiotic 
diet contains 8% fiber from inulin while the vehicle control diet contains 8% fiber 
from cellulose.  
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Figure 3-1 Food intake and body weight  
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Figure 3-1 Food intake and body weight.   
 
Food intake and body weight of E3FAD and E4FAD mice fed either the 
prebiotic or control diet for 4-months beginning at 3-months of age. a Inulin fed 
mice had no differences in food intake. b Inulin fed mice had no differences in 
body weight. Statistics were completed using 2-way ANOVA (N = 15/group, M:F 
= 50/50). Error bars show mean ± SEM.   
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Figure 3-2 Cecum weight and cecal metabolites 
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Figure 3-2 Cecum weight and cecal metabolites 
Cecum weight and cecal metabolites. The cecum, with cecal contents 
intact, was weighed upon sacrifice when the mice were around 7-months of age. 
The cecal contents of the mice were then collected and sent to Metabolon 
(Durham, NC) for metabolomics profiling via LC-MS/MS. For more details, see 
Chapter 2, section 2.5. a Both E3FAD and E4FAD mice fed inulin saw a 
significant increase in cecum weight. Similarly, the cecal contents of both E3FAD 
and E4FAD inulin fed mice saw a significant increase in b acetate, c propionate, 
and d butyrate but a decrease in e cecal isobutyrate. Statistics were completed 
using 2-way ANOVA (N = 6-8/group, M:F = 50/50). Error bars show mean ± 
SEM, ns = not significant; *p < 0.05; **p < 0.01, ***p < 0.001; ****p < 0.0001. 
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Table 3-2 Cecal metabolites – short chain fatty acids 
Short Chain 
Fatty Acids E3FAD Control E3FAD Inulin E4FAD Control E4FAD Inulin 
Cecal Contents Concentration Mean (µg/g) 
Concentration 
Mean (µg/g) 
Concentration 
Mean (µg/g) 
Concentration 
Mean (µg/g) 
Acetic Acid 1848  106.1 2817.5  305.4* 1642  213 2614  251.9* 
Propionic Acid 394.1  31.6 864  76.2* 312.3  30.7 644.3  50.4*a 
Isobutyric Acid 77.2  4.5 37.95  6.8* 64.3  8.5 44.9  5.4 
Butyric Acid 590.9  33.3 1575.9  249.4* 521.4  91.1 1083  197.1* 
2-Methylbutyric 
Acid 47.9  3.8 37.96  7.8 36.7  4.8 39.3  5.5 
Isovaleric Acid 47.8  6.5 24.73  8.1* 43.5  7.4 26.3  2.7* 
Valeric Acid 78  11.8 70.58  14.4 73.5  12 65.7  3.3 
Hexanoic Acid 2.3  0.3 2.81  1.4 1.9  0.4 1.8  0.2 
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Table 3-2 Cecal metabolites – short chain fatty acids. 
 The prebiotic inulin altered short chain fatty acid production in the cecal 
contents. Acetic acid, propionic acid, and butyric acid were significantly increased 
in the E3FAD and E4FAD mice fed the prebiotic inulin compared to their 
respective controls. In contrast, isobutyric acid and isovaleric acid were 
significantly decreased. Further, propionic levels in the E4FAD mice fed the 
prebiotic inulin were significantly decreased compared to E3FAD mice fed the 
prebiotic control. Statistics were completed using 2-way ANOVA (N = 8/group) 
with data presented as mean  SEM. *p < 0.05 comparing E3FAD and E4FAD 
mice fed the prebiotic inulin to their control fed counterparts; ap < 0.05 comparing 
E4FAD mice fed the prebiotic inulin to E3FAD mice fed the prebiotic inulin. 
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Figure 3-3 Scyllo-inositol fecal culture experiment  
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Figure 3-3 Scyllo-inositol fecal culture experiment 
Scyllo-inositol levels in fecal culture. Fecal samples of 7-month old E3FAD 
and E4FAD mice (M:F = 50/50) on a standard chow diet were collected and 
pooled into their respective groups and fecal cell suspensions were made under 
anaerobic conditions. The samples were given either inulin or a control, glucose, 
for 24 or 48 hours at which point the supernatant was collected and measured for 
scyllo-inositol via NMR. For more details, see Chapter 2, section 2.2. a In fecal 
culture, bacteria from the E3FAD mice that were given inulin saw significant 
increases in scyllo-inositol compared to those that received the control while 
bacteria from E4FAD mice saw an insignificant increase. The E3FAD inulin 
culture samples saw a significantly greater increase in scyllo-inositol when 
compared to the E4FAD inulin culture samples. Statistics were completed using 
2-way ANOVA (groups were run in triplicate). Error bars show mean ± SEM, * p < 
0.001 between conditions, # p < 0.05 between groups.  
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Figure 3-4 Gut microbiota diversity  
  
  
 
 73 
Figure 3-4 Gut microbiota diversity  
E3FAD and E4FAD - and -diversity. Fecal samples were collected from 
each mouse upon reaching 7-months of age followed by DNA extraction and 
amplification. The DNA was then shipped to UIC for 16S rRNA sequencing and 
subsequent diversity and taxonomy data analysis. For more details, see Chapter 
2, section 2.3. E3FAD mice fed the prebiotic inulin saw a significant difference in 
a α- (Gausian link function results, p = 0.00000943) and b β-diversity (ANOSIM R 
statistic = 0.877, p-value = 0.001). E4FAD saw no difference in c α- (Gausian link 
function results, p = 0.418) but a significant difference in d β-diversity (ANOSIM 
R statistic = 0.454, p-value = 0.001) (N = 15/group, M:F = 50/50).   
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Table 3-2 Gut microbiota taxonomy 
 
Taxonomic differences at the genus level between E3FAD and E4FAD 
prebiotic and control fed mice. Diet and genotype p- and q-values were 
calculated for each taxon along with each group. LogFC (log (fold change)) and 
LogCPM (base intensity of taxon (log (average counts per million))) were 
calculated for each taxon of each group. Diet refers to differences between mice 
fed either the prebiotic inulin or control diet. Genotype refers to differences in 
FAD mutations with (+) referring to the mice being positive for FAD mutations 
and (–) referring to the mice being negative for FAD mutations. The data is 
written as a heat map with the darker the respective color indicative of more 
significance (N = 15/group, M:F = 50/50).   
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Chapter 4 Specific Aim 2: To identify the effects of the prebiotic inulin on 
metabolism in the periphery and central nervous system (CNS) between 
E3FAD and E4FAD mice. 
4.1 Summary  
  The gut microbiota of APOE4 carriers appears to protect against 
foodborne illness and diarrhea in childhood, showcasing the differences that may 
be found in the gut microbiota due to genetics. This may also play a role in the 
absorption of beneficial metabolites from the gut microbiota into the periphery 
and brain between E3FAD and E4FAD mice. We found that the prebiotic inulin is 
fermented into beneficial metabolites such as SCFAs and scyllo-inositol in 
Chapter 3, which may be able to reach the periphery and potentially generate 
effects on the host and reverse metabolic deficits seen in APOE4 carriers. 
PURPOSE: The objective of this aim was to identify the effects of the prebiotic 
inulin on metabolism in the periphery and central nervous system (CNS) between 
E3FAD and E4FAD mice. RESULTS: In the blood, scyllo-inositol was 
significantly increased due to the feeding of the prebiotic inulin compared to 
control fed animals in E3FAD mice but not in E4FAD mice. Meanwhile, SCFA 
levels followed suit to a moderate degree. Metabolites in the blood were also 
dramatically different between E3FAD and E4FAD mice fed the prebiotic inulin 
compared to controls and between E3FAD and E4FAD mice. This included 
tryptophan, tyrosine, pentose pathway, and TCA Cycle metabolites. Next, scyllo-
inositol was dramatically increased in the hippocampus while numerous other 
metabolites were also altered in the brain due to the prebiotic inulin. Differences 
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were also seen between E3FAD and E4FAD mice in the recently aforementioned 
metabolites. CONCLUSIONS: This aim has demonstrated that the beneficial 
metabolites that the prebiotic inulin are fermented into in the gut microbiota are 
indeed able to reach the bloodstream and brain. However, the levels of these 
metabolites that are absorbed into the blood and brain between E3FAD and 
E4FAD mice are different, having implications for prevention and treatment of AD 
and other pathologies in human APOE3 and APOE4 carriers.   
 
4.2 Introduction 
 Guerrant et al. have demonstrated that the APOE4 allele may have a 
protective effect against foodborne illness and diarrhea in underdeveloped 
countries such as in Northeast Brazil, providing a survival advantage [39, 145]. 
Thus, the gut microbiota of our E3FAD and E4FAD mice may be vastly different 
not only in the metabolites they produce from the fermentation of prebiotics, such 
as SCFAs and scyllo-inositol as demonstrated in chapter 3, but also in how these 
metabolites are absorbed and utilized in the periphery. Based on the literature, 
SCFAs can indeed be increased in the circulation [181] and have an impact on 
peripheral tissue through direct and indirect modulation of the immune system 
[182, 183]. Indeed, the SCFAs have even been found to beneficially impact the 
brain through modulation of neuroinflammation [184] and to decrease blood brain 
barrier permeability by increasing tight junction proteins [72]. It has been 
postulated that butyrate may be able to reach the brain and improve glucose 
metabolism and mitochondrial function [148]. Not only this but children 
consuming a high fiber diet were found to have better memory and learning 
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[185]. However, other gut-brain axis metabolites have also been identified 
including tryptophan-derived indole compounds [186]. One such is indole-3-
propionic acid (IPA), which has been demonstrated to protect neurons via a 
reduction in DNA damage and lipid peroxidation [187].  
 From Chapter 3, we see that the metabolite scyllo-inositol is increased in 
the fecal gut microbiota due to the feeding of the prebiotic inulin. This metabolite 
has been given as an orally administered therapeutic in AD patients [169] as it is 
able to be absorbed into the blood stream, pass through the blood brain barrier 
[159], and reach the brain. Indeed, scyllo-inositol has been demonstrated to 
decrease Aβ aggregation [159, 164-167] and, for unclear reasons, become 
altered in AD patients as evidenced in one neuroimaging study [163]. Altogether, 
the gut-brain axis involves a variety of metabolites, many of which may be 
unknown, that can benefit the brain and metabolism thereof. However, the 
production, absorption, and usage of these beneficial metabolites may vary 
between APOE3 and APOE4 carriers. This may be of vast importance as carriers 
of the APOE4 allele display an altered brain metabolism and exhibit metabolic 
dysfunction via impaired glucose, ketone, and mitochondrial metabolism decades 
before the onset of the disease [188]. Further, hypometabolism of the brain has 
been exhibited in APOE4 carriers in studies that utilize FDG PET imaging to 
measure cerebral metabolic rates of glucose [189] while mitochondrial 
dysfunction has also been linked to the disease [190]. Collectively, these 
impairments due to the APOE4 allele, dependent and independent of Aβ, lead to 
an increased risk to develop AD [191] and we believe that the beneficial 
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metabolites from the fermentation of prebiotics may help alleviate these 
symptoms. 
 The objective of this aim was to identify the effects of the prebiotic inulin 
on metabolism in the periphery and central nervous system (CNS) between 
E3FAD and E4FAD mice. We hypothesized that the prebiotic inulin will 
beneficially alter metabolism in the periphery and CNS via increased beneficial 
metabolites in E3FAD and E4FAD mice. Specifically, we examined plasma and 
hippocampal scyllo-inositol, increased due to feeding of the prebiotic inulin in the 
gut microbiota, and metabolites associated with the gut microbiota in the plasma 
and brain.  
 
4.3 Results 
4.3.1 Plasma Scyllo-Inositol and SCFAs 
After demonstrating that scyllo-inositol was indeed formed by gut 
microbiota bacteria, we set out to see if scyllo-inositol was absorbed and reached 
the bloodstream in our mice. By using NMR, we found that in the plasma of 
E3FAD mice that were fed the prebiotic inulin, there was significantly higher 
scyllo-inositol levels compared to mice given the control diet, however, this was 
not the case in the E4FAD mice. Moreover, the control fed E4FAD mice had a 
significant decrease in scyllo-inositol compared to the E3FAD control fed mice 
(Fig. 4.1a). SCFA levels in the blood were measured by Metabolon via LC-
MS/MS, and were also found to be changed, albeit not as significantly as in the 
cecal contents, in the mice fed the prebiotic diet. This includes acetate (Fig. 
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4.1b), propionate (Fig. 4.1c), and butyrate (Fig. 4.1d). The full panel of SCFAs 
are in Table 4.1. Collectively, these results indicate that the prebiotic inulin’s 
effect of increasing scyllo-inositol and SCFAs in the gut microbiota can indeed 
reach the periphery.   
 
4.3.2 Blood Metabolites 
With Metabolon, we found a variety of metabolites in the blood that were 
increased due to the prebiotic inulin and differences in blood metabolites 
between E3FAD and E4FAD mice (Table 4.2 and Table 4.3). Tryptophan 
metabolites were significantly increased due to the prebiotic inulin compared to 
controls. These included indoleacrylate, indolepropionate (IPA), serotonin, 
indoleacetylglycine, and N-acetyltryptophan in the E3FAD mice fed the prebiotic 
inulin and indoleacrylate and IPA in the E4FAD mice fed the prebiotic inulin. In 
contrast, tyrosine metabolites were decreased including phenol sulfate and 
phenol glucuronide in E3FAD mice fed the prebiotic inulin compared to controls. 
In both E3FAD and E4FAD mice fed the prebiotic inulin compared to controls, p-
cresol glucuronide was decreased. Next, N-acetylglutamine was increased in 
mice fed the prebiotic inulin compared to their control diet counterparts. This 
metabolite was also increased in E4FAD mice compared to E3FAD mice. Next, 
N-acetylhistidine saw a similar result except for no difference in E3FAD fed the 
prebiotic inulin compared to their control diet counterpart. N6-methyllysine and N-
acetylarginine were also both decreased in E4FAD mice compared to E3FAD 
mice.  
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Numerous pentose metabolism markers were altered in E4FAD mice fed 
the prebiotic inulin compared to controls. This included ribose, increased in both 
E3FAD and E4FAD mice fed the prebiotic inulin compared to their respective 
controls, while ribitol, ribonate, ribulose, xylose, arabitol, arabonate, and 
sedoheptulose were all significantly increased in E4FAD mice fed the prebiotic 
inulin compared to controls. The advanced glycation end-product N6-
carboxymethyllysine was significantly increased due to the prebiotic inulin in 
E3FAD and E4FAD mice compared to their control diet counterparts.  
In TCA Cycle metabolites, aconitate was increased in E3FAD mice fed the 
prebiotic inulin compared to controls while isocitric lactone, alpha-ketoglutarate, 
succinate, fumarate, and malate were increased in the E4FAD mice fed the 
prebiotic inulin compared to the E4FAD mice fed the control. In contrast, 
succinylcarnitine was decreased in both groups due to the prebiotic inulin. Next, 
myo-inositol was increased due to the prebiotic inulin in both groups while 2’-
deoxyuridine was increased in E4FAD mice compared to E3FAD mice. P-cresol 
sulfate was also decreased in both groups due to the prebiotic inulin.   
 
4.3.3 Hippocampal Scyllo-Inositol 
After reaching the bloodstream, we wanted to confirm that scyllo-inositol is 
indeed able to cross the blood brain barrier, as has been reported [159], and 
become increased in the brain. Subsets of mice per group (N = 8/group, M:F = 
50/50) were randomly chosen for MRS upon reaching 7-months of age. All mice 
were anesthetized during the experiment. In both E3FAD and E4FAD mice fed 
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the prebiotic inulin compared to controls, scyllo-inositol was drastically increased 
in the hippocampus of the brain, a region susceptible to AD pathology (Fig. 4.2a). 
An increase in scyllo-inositol was also seen in the E4FAD prebiotic fed mice 
compared to the E3FAD prebiotic fed mice. A representative MRS spectra for 
each are showcased with the arrow pointing to scyllo-inositol (Fig. 4.2b, Fig. 4.2c, 
Fig. 4.2d, Fig. 4.2e). These results indicate that the prebiotic inulin’s effect of 
increasing scyllo-inositol in the gut microbiota and plasma can reach the 
hippocampus of the brain and provide dramatic increases in both E3FAD and 
E4FAD mice. However, the E4FAD mice fed the prebiotic diet saw an even 
greater increase in scyllo-inositol compared to E3FAD mice fed the prebiotic diet, 
indicative that the E4FAD mice may have less scyllo-inositol absorbed from the 
gut but greater absorption into the brain. Whether this effect is a protective 
mechanism in E4FAD mice, as scyllo-inositol has not only been determined to 
inhibit Aβ aggregation but also provide an anti-inflammatory effect, albeit likely 
from the inhibition of Aβ [165], remains to be seen. 
 
4.3.4 Brain Metabolites 
The prebiotic inulin altered numerous brain metabolites (Table 4.4), 
measured by Metabolon, in both E3FAD and E4FAD mice. There were also 
differences between E3FAD and E4FAD mice themselves. Firstly, N-
acetylglutamine, N-acetylhistidine, homocarnosine, N-acetylphenylalanine, N-
acetyltyrosine, N-acetylglucosaminylasparagine, palmitoleoyl ethanolamine, 
glycerophosphoinositol, 1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC, 2’deoxyuridine, 
 
 83 
ascorbate, and pyridoxamine were significantly increased in E4FAD mice 
compared to E3FAD mice. In contrast, N6-methyllysine, 2-aminoadipate, N-
acetylarginine, mannonate were decreased in E4FAD mice compared to E3FAD 
mice. The prebiotic inulin caused an increase in imidazole propionate, N6-
carboxymethyllysine, acetylcarnitine, and scyllo-inositol in both groups. In 
contrast, the prebiotic inulin caused a decrease in myo-inositol and p-cresol 
sulfate.  
 
4.4 Discussion 
In Chapter 3, we saw that scyllo-inositol was drastically increased during 
our fecal culture experiment, especially so in E3FAD mice. The next step was 
seeing if these changes could reach the blood stream. We see that in the plasma 
of E3FAD mice fed the prebiotic inulin, scyllo-inositol is indeed significantly 
increased compared to controls. However, there was no difference seen in the 
E4FAD mice. In fact, even when comparing E3FAD and E4FAD mice fed the 
control diet, scyllo-inositol was significantly greater in the E3FAD mice. It is 
possible that the level of scyllo-inositol in the plasma may be somewhat 
dependent on when the mice eat and when that food is fermented and absorbed 
into the bloodstream and this may have impacted the results seen in the E4FAD 
mice. However, it is more likely that less scyllo-inositol is absorbed from the gut 
by E4FAD mice compared to E3FAD mice for reasons that are currently unclear 
but has important implications for APOE4 carriers. This could even be due to 
receptor or transporter differences in the gut or perhaps scyllo-inositol is binding 
to metabolites or other metabolic products that are produced more so in E4FAD 
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mice with subsequent clearance via the fecal matter. Our next step was to see if 
scyllo-inositol was able to be increased in the brain, specifically in the 
hippocampus, a region susceptible to AD pathology and important for learning 
and memory [192]. In fact, we saw a dramatic increase in hippocampal scyllo-
inositol in both E3FAD and E4FAD mice that were fed the prebiotic inulin with the 
E4FAD mice having an even greater increase. In Chapter 3, we saw that the 
E4FAD mice had an increase in scyllo-inositol in the fecal culture experiment but 
to a lesser extent than the E3FAD mice fed the prebiotic inulin. Further, previous 
results in this chapter indicated that less scyllo-inositol is being produced by the 
gut microbiota and absorbed into the blood in E4FAD mice fed the prebiotic inulin 
compared to E3FAD mice fed the prebiotic inulin. Despite this, it appears that 
scyllo-inositol is taken into the brain at a higher rate in E4FAD mice compared to 
E3FAD mice. When comparing E3FAD and E4FAD mice fed the control, there 
was no significant difference in scyllo-inositol although there was a slight 
increase in E4FAD mice compared to the E3FAD mice. Notably, scyllo-inositol 
has been demonstrated before to be increased in AD patients [163]. We suspect 
this may be due to a compensatory mechanism in an attempt to decrease 
inflammation and halt A aggregation in the brain in APOE4 carriers. Due to the 
fact that scyllo-inositol has been demonstrated to inhibit A aggregation and 
through this, decrease inflammation, these outcomes will be further explored in 
Chapter 5. Nevertheless, these results are quite intriguing and deserve further 
attention as to why APOE4 carriers may have differences in production and 
absorption of certain metabolites into the periphery and brain. 
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In Chapter 3, we also saw that the SCFAs were dramatically increased in 
the cecal contents and we wanted to see if these metabolites were absorbed into 
the bloodstream. Here, we do see that the prebiotic inulin increased SCFAs in 
the bloodstream but to a much lesser degree than that of the cecal contents. 
There are a number of reasons for this. Firstly, SCFAs can be taken up by 
colonocytes and especially in the case of butyrate, used as an important energy 
source [154]. Next, the liver takes up and clears SCFAs in the portal circulation 
as too high of levels may become toxic. Here in the liver, the SCFAs can act as 
precursors to other processes. The SCFAs can also activate G protein-coupled 
receptors, such as Ffar2 and Ffar3, that help regulate glucose and lipid 
metabolism and can be found on immune cells [154]. Receptors expressed by 
other organs are likely present, but little is known about them at this time. Finally, 
SCFAs can also simply be excreted through the fecal contents [154]. Whether 
this increase in the bloodstream leads to a decrease in AD pathology is a 
question that will be addressed in the next chapter.  
 We next looked a variety of other metabolites that were altered in the 
whole blood of our mice and saw vast differences. Firstly, dramatic changes were 
seen in tryptophan and tyrosine metabolism, especially in our E3FAD mice fed 
the prebiotic inulin. Indeed, indoleacrylate, IPA, serotonin, indoleacetylglycine, 
and N-acetyltryptophan were all increased in E3FAD mice while only 
indoleacrylate and IPA were increased in E4FAD mice. In fact, even more 
dramatic increases were seen in the E4FAD mice in these two metabolites. 
Tryptophan metabolism in the gut includes metabolization of tryptophan to either 
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kynurenine, serotonin, and/or indole pathways, the latter two shown here. The 
serotonin pathway is important as 90% of serotonin is produced in the gut, 
although peripheral serotonin does not often cross the BBB but may 
communicate with the CNS nonetheless [193] and activate receptors in the gut 
that increase satiety and absorption of nutrients [194]. Although much is not 
understood about this process, SCFAs have been implicated in initiating 
serotonin biogenesis. Due to the increase in SCFAs we saw in the cecal 
contents, this increase in serotonin would make sense here although there was 
only a significant increase in serotonin in E3FAD mice fed the prebiotic inulin.  
Further, IPA, a part of the indole pathway through tryptophan metabolism, has 
been shown to inhibit A aggregation [85] and here we see that the prebiotic 
inulin can indeed increase this metabolite in both groups. Next, metabolites that 
play a role in tyrosine metabolism were decreased due to the prebiotic inulin 
including phenol sulfate, phenol glucuronide, and p-cresol glucuronide in E3FAD 
mice. E4FAD mice fed the prebiotic inulin only saw a decrease in p-cresol 
glucuronide. One study using resistant maltodextrin in mice found a decrease in 
both phenol sulfate and p-cresol sulfate, linking them both to inflammation [195]. 
Bacteroides, which we saw decreased in E3FAD mice fed the prebiotic inulin, 
has been linked to their production, however, Bifidobacterium has been linked as 
well [196]. Overall, there is surprisingly little known on tyrosine metabolites and 
we hope our results shed some light on this matter. Collectively, it appears that 
the prebiotic inulin increases tryptophan metabolism in the gut microbiota while 
decreasing tyrosine metabolism.  
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 Next in the blood, we found that N-acetylglutamine and N-acetylhistidine 
were both increased in the E4FAD mice compared to the E3FAD mice with the 
prebiotic inulin increasing N-acetylglutamine in both E3FAD and E4FAD mice. 
N6-methyllysine and N-acetylarginine were decreased in the E3FAD mice 
compared to E4FAD mice. Next, N6-carboxymethyllysine was increased in both 
E3FAD and E4FAD mice fed the prebiotic inulin compared to controls. Due to the 
prebiotic inulin, myo-inositol was increased in both groups while in the E4FAD 
mice compared to E3FAD mice, it was also increased. 2’-deoxyuridine saw a 
decrease in E3FAD mice fed the prebiotic inulin but an increase in E4FAD mice 
compared to E3FAD mice. Finally, p-cresol sulfate saw significant decreases in 
both E3FAD and E4FAD mice fed the prebiotic inulin. Little is known on these 
metabolites aside from the aforementioned myo-inositol and p-cresol sulfate.  
 A variety of metabolites involved in Pentose Phosphate Pathway (PPP) 
metabolism, responsible for NADPH production, were dramatically increased in 
the E4FAD mice fed the prebiotic inulin compared to E4FAD control mice. This 
includes ribose, ribitol, ribonate, ribulose, xylose, arabitol, arabonate, and 
sedoheptulose. Ribonate, xylose, and sedoheptulose were increased in the 
E4FAD mice compared to E3FAD mice. It is not currently known why E4FAD 
mice fed the prebiotic inulin would have such increases in these metabolites 
while the E3FAD mice fed the prebiotic inulin do not. However, one study did find 
an increase in the PPP linking it as a way for neurons to get energy as an 
alternative to glucose [27] as APOE4 carriers do indeed have hypometabolism 
and alterations in glucose metabolism. This paper further postulated that 
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changes in the PPP may be a novel target that connects APOE4 to changes in 
glucose metabolism and oxidative stress. Further confirming this idea, we also 
found changes in the TCA cycle especially in E4FAD mice fed the prebiotic inulin 
with significant increases in isocitric lactone, alpha-ketoglutarate, succinate, 
fumarate, and malate compared to E4FAD mice fed the control. In contrast, a 
significant decrease was seen in succinylcarnitine. The E3FAD mice fed the 
prebiotic inulin only saw significant increases in aconitate and alpha-
ketoglutarate but also an insignificant decrease in succinylcarnitine. Similar to the 
changes found in E4FAD mice fed the prebiotic inulin in the PPP, we see large 
changes in the TCA cycle, indicative of altered glucose metabolism. Again, it is 
unusual that there were so few differences between the E3FAD and E4FAD mice 
themselves especially given that it is known that APOE4 carriers have alterations 
in glucose metabolism. It is quite unclear why the prebiotic inulin would be 
causing such dramatic effects in only E4FAD mice fed the prebiotic inulin, but we 
hope this is indicating that the prebiotic inulin is decreasing the hypometabolism 
and metabolic alterations that occur in APOE4 carriers as they age. 
 Our results indicate that numerous markers were altered in the brain due 
to the prebiotic inulin and differences between E3FAD and E4FAD mice were 
also present. Firstly, N-acetylglutamine, N-acetylhistidine, homocarnosine, N-
acetylphenylalanine, N-acetyltyrosine, N-acetylglucosaminylasparagine, 
palmitoleoyl ethanolamine, glycerophosphoinositol, 1-(1-enyl-palmitoyl)-2-
palmitoleoyl-GPC, 2’deoxyuridine, ascorbate, and pyridoxamine were 
significantly increased in E4FAD mice compared to E3FAD mice. N-acetyl amino 
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acids have been found to be altered in the gut microbiota when compared to 
germ-free mice [197]. In contrast, N6-methyllysine, 2-aminoadipate, N-
acetylarginine, mannonate were decreased in E4FAD mice compared to E3FAD 
mice. The prebiotic inulin caused an increase in imidazole propionate, N6-
carboxymethyllysine, acetylcarnitine, and scyllo-inositol in both groups. In 
contrast, the prebiotic inulin caused a decrease in myo-inositol and p-cresol 
sulfate. Many of these differences were also present in the blood of the mice. 
Myo-inositol was increased in the blood due to the prebiotic inulin in both groups 
but decreased in the brain while scyllo-inositol, confirming the MRS findings in 
this chapter, was increased in both groups as well. Myo-inositol is thought to be 
increased in the asymptomatic stages of AD [198] but scyllo-inositol treatment 
has been shown to decrease its levels and improve neuropsychiatric symptoms 
[199]. In one study, Yamashita et al. believed it was possible that myo-inositol 
could be converted to scyllo-inositol in blood and skeletal muscle [161] but the 
evidence was fairly weak. Further, due to the increases in scyllo-inositol seen in 
the gut and blood of our mice fed the prebiotic inulin, this seems unlikely to be a 
major cause of the scyllo-inositol increase seen here in the brain. P-cresol sulfate 
was decreased in both groups due to the prebiotic inulin in both the blood and 
brain and has been linked to inflammation [195]. In contrast, N6-
carboxymethyllysine, an advanced glycation-end product, was increased in both 
groups in the blood and brain due to the prebiotic inulin. While this could be 
considered a new gut-brain axis component, advanced glycation-end products 
have been implicated in diabetes [200]. This metabolites role in the brain is 
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unknown. N-acetylglutamine was increased due to the prebiotic inulin in both 
groups in the blood but not in the brain. Meanwhile, E4FAD mice also saw an 
increase in this metabolite in both the blood and brain compared to E3FAD mice. 
Finally, N-acetylhistidine, N-acetylarginine, and N6-methyllysine were decreased 
in both the blood and brain in E4FAD mice compared to E3FAD mice. However, 
little is known about these metabolites. 
 Collectively, the prebiotic inulin caused a vast array of metabolic changes 
in the blood and brain of both E3FAD and E4FAD mice fed the prebiotic inulin 
compared to controls while changes between E3FAD and E4FAD mice were also 
evident. It is also notable that the prebiotic inulin was able to enhance the 
metabolism of multiple GBA components: SCFAs, IPA, and the newly discovered 
scyllo-inositol. Whether these changes will make an impact in the brain and 
decrease AD pathology will be the subject of Chapter 5.   
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Figure 4-1 Plasma scyllo-inositol and SCFAs 
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Figure 4-1 Plasma scyllo-inositol and SCFAs 
Plasma scyllo-inositol and SCFAs. E3FAD and E4FAD mice were 
sacrificed at around 7-months of age with plasma and whole blood collected. 
Plasma scyllo inositol was measured via NMR. More details can be found in 
Chapter 2, section 2.4. For blood SCFA measurement, Metabolon utilizes LC-
MS/MS. More details can be found in Chapter 2, section 2.5. a Scyllo-inositol in 
the plasma of E3FAD and E4FAD mice found a significant increase between 
E3FAD mice fed the prebiotic inulin and their respective control group. Plasma 
scyllo-inositol levels were also significantly increased in E3FAD mice compared 
to E4FAD mice. b Other metabolites increased due to the prebiotic diet include 
the SCFAs butyrate, propionate, and acetate but the only significant increase 
was acetate in the E3FAD mice fed the prebiotic inulin compared to their 
respective control group. Statistics were completed using 2-way ANOVA (For 
plasma scyllo-inositol measurement, N = 10/group (M:F = 50/50) and for SCFA 
measurement, N = 8/group (M:F = 50/50). Error bars show mean ± SEM, ns = 
not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.  
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Table 4-1 Blood metabolites – short chain fatty acids 
Short Chain Fatty 
Acids E3FAD Control E3FAD Inulin 
E4FAD 
Control E4FAD Inulin 
Blood Concentration Mean (ng/mL) 
Concentration 
Mean (ng/mL) 
Concentration 
Mean (ng/mL) 
Concentration 
Mean (ng/mL) 
Acetic Acid 2290  490.9 5012.5  1274.9 1918  261.1 6632  1410.3* 
Propionic Acid 112.6  20.6 242.9  73.3 82  10.3 145.9  31.9 
Isobutyric Acid 35.3  4.7 35.6  4.8 25.4  3 29.9  5.2 
Butyric Acid 157.9  20.5 257.1  96 144.4  33.9 222.6  22.7 
2-Methylbutyric Acid 24.6  3.5 27.7  3.6 20.8  2.9 31.8  7.3 
Isovaleric Acid 8.8  1.9 7.1  1 8.6  1.5 6.7  1.9 
Valeric Acid 10  3.3 10.8  3.5 5.4  1.9 12.6  5.7 
Hexanoic Acid 51.9  5.7 42.3  6.7 60.9  17 70.4  11.6 
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Table 4.1 Blood metabolites – short chain fatty acids 
 
 A table showcasing the levels of short chain fatty acids in the blood. 
E4FAD mice fed the prebiotic inulin saw a significant increase in propionic acid 
compared to E4FAD mice fed the control diet. Statistics were conducted using 2-
way ANOVA (N = 8/group, M:F = 50/50) with data presented as mean  SEM. *p 
< 0.05. 
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Table 4-2 Blood metabolites – tryptophan and tyrosine metabolism 
 
 A table showcasing the changes in tryptophan and tyrosine metabolites, 
and other select metabolites, due to the prebiotic inulin and differences between 
E3FAD and E4FAD mice in the blood. The whole blood of the mice was sent to 
Metabolon (Durham, NC) for metabolomic profiling. For more details, see 
Chapter 2, section 2.5. Heat map of statistically significant biochemicals profiled 
when comparing groups are labeled as follows: A dark red box indicates that p < 
0.05 and the group means fold of change > 1.00. A dark green box indicates that 
p < 0.05 and the group means fold of change < 1.00. A light red box indicates 
that 0.05 < p < 0.10 and group means fold of change > 1.00. A light green box 
indicates that 0.05 < p < and group means fold of change < 1.00 (N = 8/group, 
M:F = 50/50). 
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Table 4.3 Blood metabolites – pentose metabolism and TCA cycle 
 
 A table showcasing the changes in pentose and TCA cycle metabolites, 
and other select metabolites, due to the prebiotic inulin and differences between 
E3FAD and E4FAD mice in the blood. The whole blood of the mice was sent to 
Metabolon (Durham, NC) for metabolomic profiling. For more details, see 
Chapter 2, section 2.5. Heat map of statistically significant biochemicals profiled 
when comparing groups are labeled as follows: A dark red box indicates that p < 
0.05 and the group means fold of change > 1.00. A dark green box indicates that 
p < 0.05 and the group means fold of change < 1.00. A light red box indicates 
that 0.05 < p < 0.10 and group means fold of change > 1.00. A light green box 
indicates that 0.05 < p < and group means fold of change < 1.00 (N = 8/group, 
M:F = 50/50). 
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Figure 4-2 Hippocampal scyllo-inositol  
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Figure 4-2 Hippocampal scyllo-inositol 
Hippocampal scyllo-inositol. Scyllo-inositol in the hippocampus was 
measured via MRI when the mice reached 7-months of age. Specifically, MRS 
was utilized while the mice were anaesthetized. For more details, see Chapter 2, 
section 2.6. a Scyllo-inositol was dramatically increased in the hippocampus of 
inulin-fed E3FAD and E4FAD mice compared to controls. Both groups of E4FAD 
mice saw a significant increase in scyllo-inositol when compared to their diet 
counterparts. Representative spectra are shown for (b) E3FAD Control, (c) 
E3FAD inulin, (d) E4FAD Control, and (e) E4FAD inulin groups with the arrow 
pointing to scyllo-inositol. Statistics were completed using 2-way ANOVA (N = 
8/group, M:F = 50/50). Error bars show mean ± SEM, ns = not significant; *p < 
0.05; **p < 0.01.
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Table 4-4 Brain metabolites 
 
 Mice fed the prebiotic diet had altered metabolites in the brain. Differences 
between E3FAD and E4FAD mice were also present. Upon sacrifice around 7-
months of age, the brains of the E3FAD and E4FAD mice were collected 
followed by being shipped to Metabolon (Durham, NC) for metabolomics. Heat 
map of statistically significant biochemicals profiled when comparing groups are 
labeled as follows: A dark red box indicates that p < 0.05 and the group means 
fold of change > 1.00. A dark green box indicates that p < 0.05 and the group 
means fold of change < 1.00. A light red box indicates that 0.05 < p < 0.10 and 
group means fold of change > 1.00. A light green box indicates that 0.05 < p < 
and group means fold of change < 1.00 (N = 8/group, M:F = 50/50).  
  
 
 103 
Chapter 5 Specific Aim 3: To identify the effects of the prebiotic inulin on 
AD risk factors and pathology between E3FAD and E4FAD mice. 
5.1 Summary  
AD is a progressive neurodegenerative disorder with Aβ aggregation and 
increased inflammation being two major hallmarks of the disease. APOE4 
carriers are particular susceptible to these hallmarks and have an increased risk 
of AD development compared to APOE3 carriers. However, the gut microbiota is 
able to ferment prebiotics such as inulin into metabolites, as seen in previous 
chapters, that can provide benefits to the brain, potentially decreasing AD risk 
factors and pathology in APOE4 carriers. PURPOSE: To identify the effects of 
the prebiotic inulin and the associated generated metabolites on AD risk factors 
and pathology between E3FAD and E4FAD mice compared to their respective 
control diet counterparts. Further, to compare E3FAD and E4FAD mice. 
RESULTS: The prebiotic inulin did not change CBF, amyloid- aggregation, or 
anxiety and spatial recognition, working, and reference memory. However, 
markers of inflammation revealed significant differences due to the prebiotic 
inulin. CONCLUSIONS: The prebiotic inulin was able to decrease AD risk factors 
in E4FAD mice by decreasing certain markers of inflammation. Thus, utilizing the 
prebiotic inulin, displaying effects likely via beneficial metabolites produced from 
its fermentation in the gut, as a preventative measure may be one way to 
diminish inflammation and help decrease AD risk factors. 
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5.2 Introduction 
AD is a progressive neurodegenerative disorder with a variety of 
symptoms that include memory loss and the inability to learn new things [201], 
decreased cerebral blood flow [202], and increased inflammation and Aβ 
aggregation [203]. This is especially true in APOE4 carriers who exhibit 
decreased CBF and increased BBB permeability via the activation of the 
inflammatory cyclophilin A-nuclear factor-κB-matrix-metalloproteinase-9 pathway 
[20]. Further, APOE4 carriers do indeed have increased amyloid deposition as 
evidenced in humans [204] and in APOE4 transgenic mice [205]. APOE4 carriers 
also appear to have increased inflammation. In one study displaying this in 
APOE4 transgenic mice, the APOE4 mice were demonstrated to have increased 
inflammation, via increased microglial and NF-κB gene expression, compared to 
APOE3 mice [206]. It is also thought that the increase in Aβ aggregation may 
also increase inflammation [207]. However, the gut microbiota and associated 
metabolites have literature that support the potential reversal of these symptoms, 
discussed next.  
The prebiotic inulin is fermented into a variety of metabolites that can 
benefit the brain by potentially decreasing AD pathology. Firstly, scyllo-inositol, 
increased due to feeding of the prebiotic inulin in Chapter 3, has been 
demonstrated to inhibit Aβ aggregation in in vivo and in vitro trials [159, 164-167]. 
It is thought that through this inhibition, scyllo-inositol also decreases 
inflammation [165]. Next, SCFAs produced from the fermentation of the prebiotic 
inulin, also seen in Chapter 3, decrease BBB permeability through the increase 
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of BBB tight junction proteins [72]. The SCFAs can also modulate the immune 
system through a variety of ways. One study found that SCFAs were able to 
suppress Th17 cell production, promote Treg cells from CD4+ naive T cells, and 
activate the lipin2-JIP2 pathway, all subduing inflammation [208]. They also help 
regulate T cell size and function in the colon [209]. Further, SCFAs can act as 
histone deacetylase (HDAC) inhibitors, further promoting an anti-inflammatory 
effect [210]. Specifically, sodium butyrate has been used in an AD mouse model 
to restore histone acetylation activity with effects reaching the brain as genes 
associated with learning and memory were upregulated [211].  
The objective of this aim was to identify the effects of the prebiotic inulin 
on AD risk factors, including CBF, inflammation, anxiety, and cognition, and Aβ 
aggregation between E3FAD and E4FAD mice. We hypothesized that the 
prebiotic inulin will decrease AD risk factors and Aβ aggregation in E3FAD and 
E4FAD mice. Specifically, we examined the differences between E3FAD and 
E4FAD mice and the effect of the prebiotic inulin on CBF, inflammation, 
metabolism, anxiety and cognition, and Aβ aggregation. This is the pay-off 
chapter from all our previous work!  
  
5.3 Results 
 
5.3.1 Cerebral Blood Flow 
 
Subsets of mice per group (N = 8-10/group, M:F = 50/50) were randomly 
chosen to undergo MRI. Specifically, PCASL was utilized to measure CBF while 
the mice were anesthetized. Due to CBF being decreased with age [212] and in 
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AD [213], we anticipated the prebiotic inulin may be able to impact CBF. 
However, this was not the case as the prebiotic inulin found no effect on cerebral 
blood flow in the hippocampus of the brain compared to controls. There were 
also no differences between E3FAD and E4FAD mice.  
 
5.3.2 Amyloid-β Aggregation 
In multiple in vivo and in vitro studies, scyllo-inositol has been 
demonstrated to inhibit Aβ aggregation [159, 164-167]. We took a subset of 
brains from each group of E4FAD mice when the mice were sacrificed at around 
7-months of age for Aβ staining (N = 5/group, M:F = 50/50). These were sent to 
the COCVD Pathology Research Core at the University of Kentucky to be 
embedded and sectioned onto microscope slides. Immunohistochemistry was 
then performed for identification of Aβ followed by a background stain utilizing 
NISSL. After the slides were imaged via the Aperio ScanScope XT Digital Slide 
Scanner System in the University of Kentucky Alzheimer’s Disease Center and 
uploaded to the online database, Aperio ImageScope was used to analyze total 
anti-Aβ counts. We found that the prebiotic inulin had no effect on amyloid 
deposits in E4FAD mice (Fig. 5.1a with 5.1b and 5.1c as representative images 
of each group). These results indicate that the increase in scyllo-inositol due to 
the prebiotic inulin was unable to inhibit Aβ aggregation. Perhaps if the prebiotic 
inulin was given for a longer period of time, effects may have been evident.  
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5.3.3 NanoString Array 
 
E4FAD mice were sacrificed around 7-months of age with the brains 
collected and hippocampus dissected. Next, RNA was isolated and then 
quantified via the NanoString array. Specifically, we first wanted to see if the FAD 
mutations and/or the prebiotic inulin are able to alter markers of inflammation in 
the brain. This was completed by looking at 561 gene targets, with 318 genes 
being above the background threshold. When comparing the differential 
expression between APOE4 mice with and without the FAD mutations, 52 genes 
were significantly enriched by greater than one Log2 fold change (Fig. 5.3a). 
Among these 52 genes in E4FAD mice, we next wanted to examine the effect of 
the prebiotic inulin on these 52 genes via the mean Log2 difference between 
E4FAD mice fed either the prebiotic inulin or control diet. Among the 52 genes, 4 
genes had around a 2-fold decrease in expression due the prebiotic inulin (Fig. 
5.3b). Two of these genes were significantly decreased while 2 of the genes 
were insignificantly decreased due to the prebiotic inulin. The two significantly 
decreased genes were chemokine (C-C motif) ligand 4 (CCL4) (Fig. 5.3c) and Fc 
receptor IgG low affinity 4 (Fcgr4) (Fig. 5.3f) while the insignificantly decreased 
genes were C-X-C motif chemokine 10 (CXCL10) (Fig. 5.3d) and integrin alpha X 
(Itgax) (Fig. 5.3e).    
 
5.3.4 Animal Behavior Tests 
 
We wanted to measure the impact of the prebiotic inulin on multiple animal 
behavior tests. At 7-months of age, E3FAD and E4FAD mice underwent behavior 
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testing over a two-week period starting at the same time each morning. The 
behavior tests included elevated plus maze, evaluating the anxiety of mice, open 
field test, evaluating the anxiety of the mice in a new environment, novel object 
recognition, testing spatial recognition memory, and radial arm water maze, 
testing both spatial working and reference memory. When looking at radial arm 
water maze (Fig. 5.4a), no difference was seen between mice fed the prebiotic 
inulin and control diet. This also held true for the open field test (Fig. 5.4b), 
elevated plus maze (Fig. 5.4c), and novel object recognition test (Fig. 5.4d). 
Differences were also not apparent between E3FAD and E4FAD mice.   
 
5.4 Discussion 
As one ages, a decline in CBF occurs [212] and in APOE4 carriers, a 
decline is even seen before other AD-like symptoms occur [19]. Bell et. al. 
demonstrated that the breakdown of the BBB due to the APOE4 allele may be 
responsible for this decline in CBF [20]. Interestingly, SCFAs have been 
demonstrated to impact the BBB [72] and with the increase of SCFAs in the 
periphery due to the prebiotic inulin, we anticipated an increase in CBF. Although 
it is difficult to draw definitive conclusions, we did not see a difference in CBF due 
to the prebiotic inulin. However, there were also no differences between E3FAD 
and E4FAD mice as we expected to see a decrease in E4FAD mice compared to 
E3FAD mice. This may indicate that the deficits in CBF that APOE4 is thought to 
invoke may not have occurred yet, perhaps due to the mice not being advanced 
enough in age.  
We next looked at the effect of the prebiotic inulin on amyloid aggregation. 
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In E4FAD mice that were fed either the prebiotic or control diet, there were no 
differences between groups. Due to the increases in GBA components because 
of the prebiotic inulin, we suspected that the prebiotic fed mice may see a 
significant decrease in A aggregation. However, this was not the case as no 
differences were seen between groups in E4FAD mice. If the mice had begun 
being fed before they reached 3-months of age or if we allowed the study to go 
for a longer period of time, perhaps the effects of the prebiotic inulin would have 
been more pronounced.  
 However, we do see that the prebiotic inulin was able to change markers 
of inflammation. Firstly, the effect of the FAD mutations in APOE4 mice was 
analyzed. Mice with FAD mutations have been demonstrated in the literature to 
have increases in inflammatory markers [214] and this was further confirmed 
here. Among the 52 genes that were shown to be altered due to the FAD 
mutations, there was a noticeable downward trend in the E4FAD mice fed the 
prebiotic inulin compared to the control group. Specifically, significant decreases 
were seen in CCL4 and Fcgr4 while insignificant decreases were seen in 
CXCL10 and Itgax. CCL4 is a chemokine that has been found to be increased in 
mice with the APP/PS1 mutations and has been associated with the progression 
of A in the brain [215] while also being altered in human APOE4 carriers [216]. 
Fcgr4, along with other Fcgr’s, have been found to potentially stimulate vascular 
damage and neurodegeneration while also being upregulated due to increased 
systemic inflammation, neuroinflammation, and aging [217, 218]. Next, CXCL10 
is a chemokine found in high concentrations in certain AD mouse models and 
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even in AD patients [219, 220]. In fact, cerebrospinal fluid CXCL10 
concentrations have been positively correlated with cognitive impairment [221]. 
Notably, the receptor of CXCL10 is CXCR3 and in one study using CXCR3-
deficient APP/PS1 mice, A and plaque burden were greatly reduced along with 
a decrease in behavioral impairment, showcasing the importance of this pathway 
in AD disease progression [219]. Finally, Itgax is an integrin protein that appears 
to be induced in microglia in AD [222] but is actually downregulated in APOE 
knock-out APP/PS1 mice [223]. Since inflammation is notably increased in AD 
and is an important aspect of AD pathology [224], the decrease in inflammatory 
genes seen here, especially those that appear to play a role in AD pathology and 
progression, due to the prebiotic inulin may be a convenient, translatable way for 
a nutritional intervention to decrease AD pathology over time.  
 Finally, we wanted to see if the prebiotic inulin was able to impact animal 
behavior tests. Increased anxiety is thought to be a symptom preceding AD [225] 
and diminished mental capabilities and cognition are AD symptoms [1]. Firstly, 
we did not see any differences in the elevated plus maze or open field test, two 
tests measuring the anxiety of the mice. Further, we saw no differences in radial 
arm water maze and novel object recognition test, tests that measure spatial 
working and reference memory, and spatial recognition memory, respectively. 
Oddly, we also saw no differences between E3FAD and E4FAD mice. In fact, Liu 
et. al. found behavior deficits via the Morris Water Maze, assesses spatial 
working and reference memory, and Y-maze, assesses spatial recognition 
memory, when comparing 6-month old E4FAD mice to E3FAD mice although the 
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effects were quite modest [33]. Nevertheless, perhaps if our mice were older we 
would have seen more deficits in cognition between E3FAD and E4FAD mice 
and more of an impact from the prebiotic inulin.  
 Collectively, the prebiotic inulin was able to decrease markers of 
inflammation but was unable to effect CBF, A aggregation, or any animal 
behavior tests. Notably, there were also no differences between E3FAD and 
E4FAD mice in CBF or any of the behavior tests. This may indicate the mice 
were not old enough to develop deficits in CBF, anxiety, and/or spatial working, 
reference, or recognition memory. Effects may also have been more apparent if 
the sample size was larger in certain experiments. Nevertheless, the prebiotic 
inulin was able to decrease markers of inflammation, which we believe over time 
may help decrease AD risk factors and pathology.   
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Figure 5-1 Hippocampal cerebral blood flow 
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Figure 5-1 Hippocampal cerebral blood flow  
The prebiotic inulin did not impact CBF in the hippocampus. Subsets of 
mice per group were randomly chosen upon reaching 7-months of age to 
undergo MRI. Specifically, PCASL was utilized to measure CBF while the mice 
were anesthetized. For more details, see Chapter 2, section 2.6. a E3FAD and 
E4FAD mice fed the prebiotic inulin did not see differences when compared to 
their control fed counterparts. Further, there were no differences between E3FAD 
and E4FAD mice. Statistics were conducted using 2-way ANOVA (N = 8-
10/group, M:F = 50/50). Error bars show mean ± SEM. ns = not significant. 
  
 
 114 
Figure 5-2 Amyloid- staining 
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Figure 5-2 Amyloid- staining 
Aβ staining in the brains of E4FAD mice. The mouse brains were collected 
upon sacrifice around 7-months of age and sent to the COCVD Pathology 
Research Core at the University of Kentucky to be embedded and sectioned onto 
microscope slides. Immunohistochemistry was then performed for identification 
of Aβ followed by a background stain utilizing NISSL. After the slides were 
imaged via the Aperio ScanScope XT Digital Slide Scanner System in the 
University of Kentucky Alzheimer’s Disease Center and uploaded to the online 
database, Aperio ImageScope was used to analyze total anti-Aβ counts. For 
more details, see Chapter 2, section 2.7. a E4FAD mice fed the prebiotic diet did 
not see differences in Aβ aggregation (percent load) in the brain. b 
Representative image of E4FAD mice fed the control diet. c Representative 
image of E4FAD mice fed the prebiotic diet. Statistics were conducted using 2-
way ANOVA (N = 5/group, M:F = 50/50). Error bars show mean ± SEM. ns = not 
significant. 
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Figure 5-3 NanoString array analysis 
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Figure 5-3 NanoString array analysis 
 
 The impact of the FAD mutations and prebiotic inulin on markers of 
inflammation. E4FAD mice were sacrificed around 7-months of age with the 
brains collected and hippocampus dissected. Next, RNA was isolated and then 
quantified via the NanoString array. For more details, see Chapter 2, section 2.8. 
a In APOE4 mice with and without the FAD mutations, data are plotted as the 
mean ratio expression with their respective adjusted p-value. This revealed 52 
genes that were significantly differentially enriched (magenta) with greater than 
one Log2 fold change due to the FAD mutations. b The 52 genes that were 
enriched due to the FAD mutations were further examined under the context of 
diet manipulation. Overall, there was a trend for most of the 52 genes to be 
downregulated due to the prebiotic inulin in E4FAD mice. Further, a 2-fold 
decrease in expression was seen in 4 genes (aquamarine). Among these, c 
CCL4, and f Fcg4 were significantly decreased and d CXCL10 and e Itgax were 
insignificantly decreased due to the prebiotic inulin. Statistics were completed 
using 2-way ANOVA (Sidak posthoc multiple comparisons correction) (N = 
5/group, all male). For more details, see section 2.8. Error bars show mean ± 
SEM, ns = not significant; *p < 0.05. 
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Figure 5-4 Behavior tests 
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Figure 5-4 Behavior tests 
 
 The impact of the prebiotic inulin on animal behavior tests. At 7-months of 
age, E3FAD and E4FAD mice underwent behavior testing over a two-week 
period starting at the same time each morning. The behavior tests included 
elevated plus maze, evaluating the anxiety of mice, open field test, evaluating the 
anxiety of the mice in a new environment, novel object recognition, testing spatial 
recognition memory, and radial arm water maze, testing both spatial working and 
reference memory. For more details, see section 2.9. In E3FAD and E4FAD mice 
fed the prebiotic inulin compared to their control fed counterparts and when 
comparing E3FAD and E4FAD mice, no differences were seen in a radial arm 
water maze, b open field test, c elevated plus maze, or d novel object 
recognition. All behavior tests were conducted in the Rodent Behavior Center at 
the University of Kentucky when the mice reached 7-months of age. Statistics 
were conducted using 2-way ANOVA (N = 7-9/group, M:F = 50/50). Error bars 
show mean ± SEM. ns = not significant.  
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Chapter 6 General Discussion 
6.1 Discussion 
This project uncovered many remarkable findings that will prove to be 
impactful in the field. Firstly, we see that the prebiotic inulin is able to significantly 
alter the gut microbiota in both E3FAD and E4FAD mice. Not only this but the 
response of the mice to the prebiotic inulin was different to where E3FAD mice 
appear to gain more benefit than do E4FAD mice. This includes greater 
increases in beneficial taxa such as Bifidobacteria, Lactobacillus, and 
Akkermansia in the E3FAD mice. Interestingly, we found that due to the prebiotic 
inulin, scyllo-inositol was increased by the fecal microbiota population and that 
the SCFAs levels were also considerably higher in the cecal contents. 
Amazingly, the E4FAD mice fed the prebiotic inulin had less of an increase in 
scyllo-inositol, propionate, and butyrate than did the E3FAD mice fed the 
prebiotic inulin, indicative that the gut microbiota of E4FAD mice are unable to 
produce as much beneficial metabolites. Due to work by Dr. Richard Guerrant 
where children who were APOE4 carriers were more resistant to enteric infection 
and thus had improved cognition [226], our lab thought E4FAD mice in our study 
may have a more beneficial gut microbiota. We did not come to such a 
conclusion based on our data but the benefits of the APOE4 allele during 
development have been well noted in the literature [227]. Nevertheless, it is 
possible that the gut microbiota of APOE4 carriers is resistant to enteric infection 
but for reasons we have yet to understand. Further, the gut of APOE4 carriers 
may need a higher dosage of prebiotics to receive similar benefits compared to 
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APOE3 carriers and this should be considered when looking improve the gut 
health of APOE4 carriers. Also in the gut microbiota, we found no notable 
differences due to the FAD mutations in either E3FAD or E4FAD despite other 
studies indicating that these mutations increased amyloid-like proteins in the gut 
[40] and impacted amyloid deposition in the brain [41]. Notably, a slightly different 
AD mouse model was used in these studies that involved just the APP and PS1 
mutations and at different ages than our study. While it is still certainly possible 
that the APOE4 allele provides protection against enteric infection and certain 
FAD mutations alter the gut microbiota, we cannot confirm such effects.   
One important aspect of the gut microbiota is how much of the benefits 
actually make it to the periphery and play a role on the host. In our project, we 
see that scyllo-inositol, SCFAs, and even IPA are increased due to the prebiotic 
inulin in the blood. However, E4FAD mice saw little scyllo-inositol in the blood in 
either the prebiotic or control group. Nevertheless, this is a landmark finding as 
inulin is seen here to increase multiple GBA components and we are able to 
declare scyllo-inositol a GBA component for the first time. Not only this but there 
were many other metabolic differences that were altered due to the prebiotic 
inulin in both E3FAD and E4FAD mice. There was an increase in tryptophan 
metabolism and a decrease in tyrosine metabolism. While we cannot assuredly 
say this will benefit the host, although the increase in the tryptophan metabolite 
IPA may be beneficial due to its inhibitory effects on A aggregation [85], this is a 
major finding in the prebiotic field. It would be of interest if these findings could be 
repeated with other prebiotics. Also, in the blood, we also found differences in the 
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PPP and TCA Cycle. While it is known that APOE4 carriers develop 
hypometabolism and have altered glucose metabolism [228], the PPP has been 
recently implicated [27] and may be a research avenue that needs more 
exploring.   
The next step in the project was to see if the effect of the prebiotic inulin in 
the gut microbiota could not only reach the periphery but also the brain. Here we 
do indeed see that scyllo-inositol was increased in the hippocampus of both 
E3FAD and E4FAD mice fed the prebiotic inulin. Contrary to what you may think 
due to the findings in Chapters 3 and 4 where greater increases in scyllo-inositol 
in the gut and absorption thereof into the periphery were found in E3FAD mice 
compared to E4FAD mice fed the prebiotic inulin, the E4FAD mice actually saw a 
greater increase in hippocampal scyllo-inositol compared to E3FAD mice. This 
indicates that E4FAD mice may have a compensatory effect, perhaps due to 
increased inflammation in the brain, that enables more scyllo-inositol, which can 
decrease inflammation via inhibition of A aggregation [165], to be brought into 
the brain compared to E3FAD mice. Reasons how this occurs are not available 
as scyllo-inositol is a little studied metabolite. It is also plausible that myo-inositol 
could be converted to scyllo-inositol, or vice-versa in the blood and/or brain but 
the only evidence of this is in the blood [161]. In this study, scyllo-inositol was 
administered in the blood of mice with a subsequent increase seen in myo-
inositol levels. This evidence is not particularly strong, but the possibility still 
remains.  
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The next and final step was to see if the changes due to the prebiotic inulin 
were able to not only reach the periphery and brain but to also decrease AD risk 
factors and pathology. We did indeed see alterations in inflammation in mice fed 
the prebiotic inulin, but many AD risk factors and pathology were not altered. This 
included no differences seen in CBF, anxiety and cognition, and A aggregation. 
Due to the increase in gut-brain axis components that have literature supporting 
their ability to inhibit A aggregation, we suspected the prebiotic inulin may 
indeed be able to decrease A. However, this was not the case. It is possible if 
we began the prebiotic diet on the mice at an earlier age or fed them for a longer 
period of time, then differences would become more evident. Nevertheless, we 
did see a notable downward trend in inflammatory genes due to the prebiotic 
inulin via a decrease in 52 genes that were increased by the FAD mutations. 
Among these, CCL4 and Fcgr4 were significantly decreased while CXCL10 and 
Itgax were insignificantly decreased. It is quite notable that these aforementioned 
inflammatory markers have been associated with AD pathology and disease 
progression. Due to this, we do indeed believe the consumption of the prebiotic 
inulin may be a convenient, translatable way to decrease AD risk factors and 
pathology over time.  
 Collectively, we see that the prebiotic inulin is able to increase numerous 
components of the gut-brain axis that were able to reach the brain. In fact, a new 
gut-brain axis component has been revealed in scyllo-inositol. A aggregation 
and numerous AD risk factors were unable to be impacted by the prebiotic inulin, 
however, markers of inflammation in the brain were decreased due to the 
 
 124 
prebiotic inulin. Overall, this research enables a paradigm shift as taking 
preventative measures to decrease AD risk factors in APOE4 carriers may be 
effective in helping to prevent the disease.  
 
6.2 Limitations 
A limitation of our project was the use of our animal model. Although we 
believe that the EFAD mouse model is the most state-of-the-art and translatable 
AD mouse model available, as it allows us to see AD pathology within just a few 
months of age in the mice, AD mouse models have historically translated poorly 
to clinical outcomes [229]. It also cannot be discounted that mice and humans 
are different species that will vary in results.  
A major limitation of Aim 1 involves the gut microbiota; however, this is the 
same limitation present with gut microbiota research in general. Although the 
method to extract DNA from the fecal sample appears to have minimal impact, 
the varying techniques used to target the bacterial 16S rRNA gene of the mice 
can impact the results and reproducibility in a major way [230]. Further, the 
husbandry of the mice also varies and can impact results, among other 
challenges [231]. In our study, the groups were split into two batches and thus, a 
batch effect was present to where a direct comparison of E3FAD and E4FAD 
mice became impossible. However, this will be considered in all our future 
endeavors.  
 Another limitation related to the gut microbiota involves scyllo-inositol. 
Bacillus subtilis is the only known bacterial taxa to increase this metabolite [155] 
and we did not find this taxon in our 16S rRNA sequenced data. We do know that 
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scyllo-inositol was increased due to our fecal bacterial culture experiment. Thus, 
we believe that other bacterial species are also able to produce this metabolite 
and identifying these taxa could be a future direction of our lab’s research.  
 In Aim 3, we found that the prebiotic inulin was unable to impact CBF and 
animal behavior tests or decrease A aggregation. This may be due to stopping 
the study before they reached an advanced enough age to develop deficits in 
CBF and in animal behavior tests. Due to the E4FAD mice not having deficits in 
CBF and in the animal behavior tests compared to E3FAD mice, we do indeed 
suspect the mice at 7-months of age were not old enough to develop such 
deficits. This may also be true in regard to the lack of decrease in A aggregation 
in E4FAD mice fed the prebiotic inulin, however, we do not necessarily believe 
that the amyloid cascade hypothesis, the hypothesis that A plaques are the 
primary culprit for the disease, is solely responsible for AD [232]. Indeed, studies 
have shown that normal cognitive people have amyloid plaques and that 
decreasing these plaques in AD patients has no effect on their symptoms [232]. 
The amyloid cascade hypothesis has also consistently failed clinically to meet 
primary endpoints although this may also be due to beginning treatment too late 
in AD pathology [232, 233].  Nevertheless, we believe with the prebiotic inulin 
able to decrease inflammation and alter the metabolism of E4FAD mice, utilizing 
this nutritional intervention may be a paradigm shift in preventing AD.  
And finally, the last notable limitation is that we did not look for 
neurofibrillary tangles, one of the primary hallmarks of the disease and potential 
causative agent of AD [234].  
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6.3 Significance and Implications 
 This project has major significance and implications towards the future of 
GBA and AD research. The findings from Aim 1 demonstrate that E3FAD and 
E4FAD mice are both able to ferment the prebiotic inulin into beneficial 
metabolites but in dissimilar amounts. Indeed, the E3FAD mice appear to get 
more benefit from the prebiotic inulin than the E4FAD mice. This indicates that 
the genetic makeup of an organism can impact the gut microbiota, their response 
to prebiotics, and ability to ferment prebiotics into metabolites. This signifies that 
personalizing treatments based on one’s genetics may be more effective in 
preventing and treating AD compared to a standard approach.  
 Aim 2 is significant because we see that the metabolites produced from 
the fermentation of the prebiotic inulin are indeed able to reach the bloodstream 
and brain to potentially exert effects. Although prebiotics may be fermented by 
the gut microbiota, their impact is exerted beyond into other organs. This may 
pave the way for other interventions that benefit the gut microbiota to come into 
the limelight, be moved into clinical trials, and eventually, used as a part of a 
personalized AD prevention plan, especially for those that are genetically 
predisposed to the disease. In this aim, we also see scyllo-inositol as a new, 
novel component of the GBA. As more and more GBA components are revealed, 
more treatment and prevention plan that look to benefit the GBA could be 
utilized. We also saw the increase in SCFAs and IPA, known GBA components, 
that provides compelling evidence that the prebiotic inulin can impact numerous 
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GBA components. Interestingly, we also saw metabolic differences between 
E3FAD and E4FAD mice in the blood and brain, indicating that the absorption of 
metabolites from the gut and impact thereof in the periphery is also different 
depending on one’s genetics.  
 Aim 3 is significant because we see that a nutritional intervention is able to 
decrease AD risk factors via diminished inflammation. Due to pharmacological 
interventions primarily failing [5], it has been suggested that preventative 
measures may be more effective in preventing and treating AD [6]. Our results 
confirm that a nutritional intervention such as prebiotics can be effective in 
helping to decrease AD risk factors, signifying a paradigm shift in how we 
approach AD care in human patients. Indeed, benefiting the gut microbiota and 
GBA may be the first preventative measure that one should undertake to prevent 
AD.   
 
6.4 Future Directions 
 The future directions for this research are vast! Firstly, a better 
understanding of what bacterial taxa produce certain metabolites would greatly 
help us understand the gut microbiota and the benefits it can produce on the 
host, including that of the taxa that produce scyllo-inositol. Next, using different 
prebiotics, such as inulin, resistant starch and galacto-oligosaccharides, and 
comparing the effects of these prebiotics to each other on the gut microbiota and 
brain would greatly influence the literature and translatability to humans. It is 
plausible that all prebiotics are able to increase the production of beneficial 
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metabolites. However, it is also possible that only the prebiotic inulin is able to 
increase scyllo-inositol while other prebiotics cannot produce scyllo-inositol but 
can increase other, unique metabolites. Combining multiple prebiotics would be 
very beneficial as well as the human diet would more likely contain a mixture of 
different foods and prebiotics as opposed to specializing in the consumption of 
just one. Subsequently, using different dosages of prebiotics and seeing if there 
is a dose-dependent effect of benefits and metabolite production would also be 
highly valuable. This could greatly impact how this research can be translated to 
humans and what exactly humans should be consuming, and in what amounts, 
for optimal gut microbiota and GBA health. Next, further understanding the 
differences between APOE3 and APOE4 carriers would help in translating 
findings to humans as a personalized approach may be more effective 
depending on one’s genes in preventing and treating AD compared to a standard 
treatment that doesn’t take this into account. However, to fully understand the 
significance and implications of this project, studies in clinical trials looking at the 
impact of the prebiotic inulin on the GBA and AD, in APOE3 and APOE4 carriers 
alike, need to be completed.  
 The final notable future direction is to feed the mice for a longer period of 
time and until the mice reach an older age. Considering there were no deficits in 
CBF and animal behavior tests between E3FAD and E4FAD mice at 7-months of 
age, it may be worth measuring these outcomes again when the mice reach 10 
or 12-months of age and then seeing the impact of the prebiotic inulin on AD 
pathology.  
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7.1 Summary  
Advancing age is the top risk factor for the development of 
neurodegenerative disorders, including Alzheimer’s disease (AD). However, the 
contribution of aging processes to AD etiology remains unclear. Emerging 
evidence shows that reduced brain metabolic and vascular functions occur 
decades before the onset of cognitive impairments, and these reductions are 
highly associated with low-grade, chronic inflammation developed in the brain 
over time. Interestingly, recent findings suggest that the gut microbiota may also 
play a critical role in modulating immune responses in the brain via the brain-gut 
axis. In this study, our goal was to identify associations between deleterious 
changes in brain metabolism, cerebral blood flow, gut microbiome, and cognition 
in aging, and potential implications for AD development. We conducted our study 
with a group of young mice (5-6 months of age) and compared those to old mice 
(18-20 months of age) by utilizing metabolic profiling, neuroimaging, gut 
microbiome analysis, behavioral assessments, and biochemical assays. We 
found that compared to young mice, old mice had significantly increased levels of 
numerous amino acids and fatty acids that are highly associated with 
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inflammation and AD biomarkers. In the gut microbiome analyses, we found that 
old mice had increased Firmicutes/Bacteroidetes ratio and alpha diversity. We 
also found impaired blood-brain barrier function and reduced cerebral blood flow 
as well as compromised learning and memory and increased anxiety, clinical 
symptoms often seen in AD patients, in old mice. Our study suggests that the 
aging process involves deleterious changes in brain metabolic, vascular and 
cognitive functions, and gut microbiome structure and diversity, all which may 
lead to inflammation and thus increase the risk for AD. Future studies conducting 
comprehensive and integrative characterization of brain aging, including 
crosstalk with peripheral systems and factors, will be necessary to define the 
mechanisms underlying the shift from normal aging to pathological processes in 
the etiology of AD. 
  
7.2 Introduction 
Advancing age increases the risk factor for developing dementia, with 
imaging and biomarker data suggesting that the pathophysiological processes of 
Alzheimer’s disease (AD) begin more than a decade prior to the diagnosis of 
dementia [23, 235-237]. However, how aging processes contribute to AD etiology 
still remains unclear. Bioenergetic imbalance over time has been considered as 
one of the primary causes for these chronic disorders [238]. In the central 
nervous system, brain energy supply declines with age [239]. Failure to maintain 
brain metabolism causes dysfunctional cellular energy status and nucleotide 
biosynthesis [240], leading to cognitive impairment and brain volume atrophy 
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[241]. In addition, this energetic imbalance leads to neuroinflammation 
accompanied by reduced neuronal activity and increased glial activation [242-
245]. Glial over-activation can cause release of inducible nitric oxide synthase 
(iNOS), which can result in inflammation and sepsis [246]. Chronic 
neuroinflammation can further lead to retention of amyloid beta (Aβ) plaques and 
tau tangles as seen in AD, and ultimately, memory loss, and dementia [224]. 
Emerging evidence shows the metabolic imbalance and inflammatory 
responses may not only originate in the brain per se, but also from gut microbiota 
[247]. The gut microbiota is the community of microorganisms in the intestines 
that contains over 1,000 different bacterial species, categorized into four primary 
phyla: Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria [248]. A 
number of studies have demonstrated that the gut microbiota changes with age 
[249-251].  In particular, an increased Firmicutes/Bacteroidetes (F/B) ratio is 
associated with increased inflammation and excess energy harvest from food in 
obese patients [252]. Increased F/B ratio is associated with the weakening of the 
epithelial tight junctions, allowing proinflammatory cytokines produced by 
pathogenic bacteria transfer to the brain from the blood stream or vagus nerve 
[72, 253]. Inflammation due to leaky gut syndrome has also been shown to 
increase the risk for anxiety and depression [254], which can exacerbate learning 
and memory performance [255, 256]. 
Leaky gut syndrome also leads to neurovascular defects, evident by 
increased blood-brain barrier (BBB) permeability [72]. The reduction of BBB 
transporters may lead to impaired clearance of Aβ [20, 237], enhancing the risk 
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of dementia like symptoms [257]. Impaired BBB function is also linked with 
reduced cerebral blood flow (CBF) [20]. Indeed, reductions in CBF with age have 
been known for years [212]. These neurovascular risks are highly associated 
with accelerated decline in language ability, verbal memory, attention and 
visuospatial abilities, and increased anxiety and depression in aging [236, 237, 
258-260]. 
Collectively, the cognitive aging and risk for AD may be driven by 
deleterious changes of brain physiology originated from the central nervous 
system as well as the peripheral systems. Nonetheless, the associations 
between brain metabolism, perfusion, cognition, and gut microbiome remain 
largely unknown. In this study, our objective was to examine the effects of aging 
on the brain and the gut in young and old mice and how these effects collectively 
alter neurological function. To achieve this, we used metabolomics for brain 
metabolite assessment, 16s ribosomal RNA (rRNA) gene amplicon sequencing 
to analyze the gut microbiome, neuroimaging to examine brain vascular 
functions, and behavioral testing to determine memory and anxiety. We 
hypothesized that age-related deleterious changes would be exhibited in the 
brain and gut, effecting brain metabolic, vascular and cognitive functions, which 
may increase the risk for developing AD. 
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7.3  Methods  
7.3.1 Animals 
Young (5-6 mo) and old (18-20 mo) male C57BL/6N mice were acquired 
from the National Institute of Aging Colony. We determined the sample size via 
power analysis to ensure comparison at a 0.05 level of significance and 90% 
chance of detecting a true difference of each measured variable between the two 
groups. Each mouse was caged individually and housed in a specific pathogen-
free facility. In order to avoid the potential for aggression when combining 
multiple male mice into one cage, mice were housed individually. Further, mice 
should be housed individually for gut microbiome analysis due to cage effects 
from microbiome transfer, e.g. mice eating each other’s feces giving them a very 
similar gut microbiome and thus, the mice would be N = 1 for that particular cage 
[113]. The mice were weighed weekly and given ad libitum access to food and 
water. All experimental procedures were performed according to NIH guidelines 
and approved by the Institutional Animal Care and Use Committee (IACUC) at 
the University of Kentucky (UK). 
 
7.3.2 Gut Microbiome Analysis 
For fecal DNA amplification, fecal samples were collected from young (N 
=39) and old (N= 28) mice and frozen at -80˚C until further use. A PowerSoil 
DNA Isolation Kit (MO BIO Laboratories, Inc.) was used for fecal DNA extraction, 
according to the manufacturer’s protocol. Genomic DNA was PCR amplified with 
primers CS1_515F and CS2_926R [114] targeting the V4-V5 regions of microbial 
 
 134 
16S rRNA genes using a two-stage “targeted amplicon sequencing (TAS)” 
protocol [115, 116]. First stage amplifications were performed with the following 
thermocycling conditions: 95˚C for 3mins, 28 cycles of 95˚C for 45sec, 55˚C for 
45sec, 72˚C for 90sec and final elongation at 72˚C for 10 minutes. Barcoding 
was performed using a second-stage PCR amplification with Access Array 
Barcode Library for Illumina Sequencers (Fluidigm, South San Francisco, CA; 
Item# 100-4876). The pooled libraries, with a 15% phiX spike-in, were loaded on 
a MiSeq v3 flow cell, and sequenced using an Illumina MiSeq sequencer, with 
paired-end 300 base reads. Fluidigm sequencing primers, targeting the CS1 and 
CS2 linker regions, were used to initiate sequencing. De-multiplexing of reads 
was performed on instrument. Second stage PCR amplification and library 
pooling was performed at the DNA Services (DNAS) facility, Research 
Resources Center (RRC), University of Illinois at Chicago (UIC). Sequencing was 
performed at the W.M. Keck Center for Comparative and Functional Genomics at 
the University of Illinois at Urbana-Champaign (UIUC). 
For microbial analysis, forward and reverse reads were merged using 
PEAR [117]. Primer sequences were identified using Smith-Watermann 
alignment and trimmed from the sequence. Reads that lacked either primer 
sequence were discarded.  Sequences were then trimmed based on quality 
scores using a modified Mott algorithm with PHRED quality threshold of p = 0.01, 
and sequences shorter than 300 bases after trimming were discarded. QIIME 
v1.8 was used to generate OTU tables and taxonomic summaries [118]. Briefly, 
the resulting sequence files were merged with sample information. Operational 
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taxonomic unit (OTU) clusters were generated in a de novo manner using the 
UCLUST algorithm with a 97% similarity threshold [119]. Chimeric sequences 
were identified using the USEARCH61 algorithm with the GreenGenes 13_8 
reference sequences [120]. Taxonomic annotations for each OTU were using the 
UCLUST algorithm and GreenGenes 13_8 reference with a minimum similarity 
threshold of 90% [119, 120]. Taxonomic and OTU abundance data were merged 
into a single OTU table and summaries of absolute abundances of taxa were 
generated for all phyla, classes, orders, families, genera, and species present in 
the dataset. The taxonomic summary tables were then rarefied to a depth of 
10,000 counts per sample. 
Shannon and Bray-Curtis indices were calculated with default parameters 
in R using the vegan library [121, 122]. The rarefied species data, taxonomic 
level 7, were used to calculated both indices.  Plots were generated in R using 
the ggplot2 library [123]. Significant difference among tested groups was 
determined using the Kruskal-Wallis one-way analysis of variance.  The group 
significance tests were performed on the rarefied species data, taxonomic level 6 
(genus), using the group_significance.py script within the QIIME v1.8 package. 
The gene amplicon sequence data generated as part of this study have 
been submitted to the NCBI BioProject database under accession number 
(PRJNA400638). 
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7.3.3 Behavior Testing 
All behavior tests were conducted over a two-week period with each test 
starting at the same time each morning. For each mouse, Elevated Plus Maze 
(EPM) was done first followed by Novel Object Recognition (NOR) the next day. 
Radial Arm Water Maze (RAWM) testing was then carried out starting the day 
after NOR. A subset of young (N = 22) and old (N =18) mice underwent three 
behavior tests. For more details on the three behavior tests, please see Chapter 
2, section 2.9.  
 
7.3.4 Cerebral Blood Flow Measurement 
A subset of young and old mice (N = 12 per group) were used to measure 
in vivo CBF using magnetic resonance imaging (MRI). For more details on this, 
please see Chapter 2, section 2.6.  
 
7.3.5 Blood-Brain Barrier Function Determination and Western Blotting 
BBB function was determined by measuring P-glycoprotein (P-gp) 
transport activity in isolated brain capillaries. P-gp is an ATP-driven transporter 
highly expressed at the BBB that facilitates transport of Aβ from brain to blood. 
This technique was previously established via a confocal imaging-based assay to 
assess P-gp transport activity in freshly isolated brain capillaries from mice [261, 
262]. This assay measures within capillary lumens accumulation of [N-ε(4-nitro-
benzofurazan-7-yl)-D-Lys(8)]-cyclosporin A (NBD-CSA), a fluorescent P-
glycoprotein substrate. 
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For capillary isolation, after euthanasia, mouse brain capillaries (N= 7 per 
group) were isolated according to a previously described protocol [261, 263]. 
Briefly, mice were euthanized by CO2 inhalation and decapitated; brains were 
immediately harvested and collected in ice-cold DPBS buffer supplemented with 
5 mM D-glucose and 1 mM Na-pyruvate, pH 7.4. Brains were dissected by 
removing meninges, choroid plexus and white matter, and homogenized in 
DPBS. The brain homogenate was mixed with Ficoll® and centrifuged at 5,800g 
for 20 minutes at 4°C. The capillary pellet was resuspended in 1% BSA buffer 
and first passed through a 300 µm nylon mesh and then through a 27 µm nylon 
mesh. Capillaries retained by the 27 µm nylon mesh were collected and washed 
with DPBS buffer and used for experiments. 
For p-glycoprotein transport activity, isolated capillaries were incubated for 
1 h at room temperature with 2 μM NBD-CSA (custom-synthesized by R. Wenger 
(Basel, Switzerland)) in DPBS buffer. Ten capillary images were acquired by 
confocal microscopy (Leica TSP SP5 Confocal Microscope with Environmental 
Chamber, 63 × D-Water UV objective, numerical aperture 1.2, Zoom: 4, 488-nm 
line of an argon laser, Leica Microsystems). Confocal images were analyzed by 
quantitating luminal NBD-CSA fluorescence with Image J software (v.1.45s; 
Wayne Rasband, NIH). Specific, luminal NBD-CSA fluorescence was taken as 
the difference between total luminal fluorescence and fluorescence in the 
presence of the P-glycoprotein-specific inhibitor PSC833 (5 μM, Novartis, Basel, 
Switzerland) [264]. 
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For western blotting and quantification to determine protein expression, 
isolated brain capillaries were homogenized in tissue lysis buffer containing a 
cocktail of protease inhibitors. Homogenized brain capillary samples were 
centrifuged at 10,000 g for 15 minutes at 4°C, followed by a centrifugation of the 
denucleated supernatants at 100,000 g for 90 minutes at 4°C. Pellets (crude 
brain capillary plasma membranes) were resuspended and protein 
concentrations were determined using the Bradford protein assay. Normalized 
brain capillary membrane samples were separated on a NuPAGE™ 4-12% Bis-
Tris Protein Gels (1.0 mm, 15-wells; Thermo Fisher Scientific, Waltham, MA, 
USA) and transferred onto an Invitrolon™ PVDF membrane (0.45 µm pore size; 
Thermo Fisher Scientific, Waltham, MA, USA) membrane using the NuPAGE® 
electrophoresis and blotting system (Invitrogen, Carlsbad, CA, USA). After 
protein transfer, the blotting membranes were incubated overnight with antibody 
to P-gp (C219; MA1-26528, ThermoFisher, 1μg/ml) and β-actin (ab8226 from 
Abcam, 1:1000, 1 μg/ml). Proteins were detected using SuperSignal® West Pico 
Chemoluminescent substrate (Pierce, Rockford, IL, USA) and protein bands 
were visualized with a BioRad Gel Doc™ XRS imaging system. P-gp was 
visualized first, membranes were then stripped with Restore™ Western Blot 
Stripping Buffer (Thermo Fisher Scientific, Waltham, MA, USA) and incubated 
with the antibody against β-actin. Image Lab 5.0 software from Bio-Rad 
Laboratories was used for densitometric analyses of band intensities and digital 
molecular weight analyses; the molecular weight marker was RPN800E (GE 
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Healthcare, Chalfont St. Giles, Buckinghamshire, UK). Linear adjustments of 
contrast and brightness were applied to entire Western blot images. 
 
7.3.6 Inducible Nitric-Oxide Synthase Measurement 
Total RNA from frontal cortex and hypothalamus homogenate (N =7-8 per 
group) was isolated using TRI Reagent solution (Ambion), and cDNA was 
synthesized from 1ug total RNA from each individual sample using SuperScript 
III (Invitrogen). qRT-PCR was performed using TaqMan real time PCR (ViiA™ 7, 
Applied Biosystems). All reactions were performed with non-template negative 
control, and all data are mean ± SEM of two independent biological replicates. 
The gene probes and master mix were also purchased from Applied Biosystems. 
The probe sets were as follows: Mm00440502-m1 (inducible nitric-oxide 
synthase (Nos2)), Mm00446968-m1 (hypoxanthine guanine phosphoribosyl 
transferase (Hprt)). The relative expression levels were measured using the 
relative quantitation ΔCt (delta counts) method and normalized to Hprt. 
 
7.3.7 Metabolomic Profiling 
Please see Chapter 2, section 2.5 for more detail.  
 
7.3.8 Statistical Analysis 
All statistical analyses were completed using GraphPad Prism (GraphPad, 
San Diego, CA, USA). One-tailed Student’s t-test was performed for 
determination of differences between groups. Levels of statistical significance 
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were reached when p < 0.05. For Metabolon, missing values in the data are 
assumed to be below the level of detection of the used instruments. Log 
transformations and imputation of missing values with the minimum observed 
values for each metabolite was conducted. This was followed by ANOVA to 
identify biochemicals that were significantly different between groups. Given the 
multiple comparisons inherent in analysis of metabolites, between-group relative 
differences are assessed using both p-value and false discovery rate analysis (q-
value). 
 
7.4 Results  
7.4.1 Altered Gut Microbiome and Increased Body Weight with Age  
Alpha diversity (e.g., Shannon index, H value) was measured for fecal 
microbial communities of all samples, at the taxonomic level of genus (Figure 
1A). Older mice had a significantly higher alpha diversity than young mice 
(Kruskal-Wallis p-value = 0.022). Although no significant differences in beta 
diversity were observed (Analysis of similarity, ANOSIM R statistic=0.006, p-
value=0.307, 999 permutations), and no specific taxa were significantly different 
between the groups of young and old mice (Kruskal-Wallis, false discovery rate, 
FDR-corrected p-value <0.05), the ratio of Firmicutes/Bacteroidetes was 
significantly different between age groups. Old mice had significantly higher 
Firmicutes/Bacteroidetes (F/B) ratio (Fig. 1B, 46% increase, p < 0.05). Further, 
we found that the body weight of the old mice was significantly higher compared 
with that of the young mice (Fig. 1C, 24% increase, p < 0.05). 
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7.4.2 Enhanced Proinflammatory Metabolism with Age 
The quantification of the brain metabolites is shown in Table 7.1. We 
observed several significant age-dependent changes in basal brain metabolites 
(after 6 hours of final feeding). Notably, the old group had a 31-83% change in 
markers of the methionine cycle with significantly greater methionine, cysteine, 
cysteine-glutathione disulfide, and cystathionine. Firstly, methionine is an amino 
acid that may be accountable for increased mitochondrial reactive oxygen 
species (ROS)[265]. Due to this, we believe the old mice exhibit increased 
oxidative stress in the brain. We also found lipids related to inflammatory 
responses significantly elevated in the old mice, including a 82% increase in 
prostaglandin D2, and a 80% increase in prostaglandin E2. Further, markers 
associated with Alzheimer’s disease (AD) were significantly greater in the old 
mice compared to the young, including a 21% increase in 24(S)-
hydroxycholesterol, 28% increase in mead acid (20:3n9), 37% increase in 
phenylalanine, 58% increase in spermidine, 22% increase in docosapentaenoate 
(n6 DPA; 22:5n6), 11% increase in creatine, and 12% increase in 
phosphocholine [266-272]. In contrast, CDP-choline, a metabolite that has shown 
to alleviate AD symptoms [273], saw a 6% decrease in the old group. In addition, 
old mice also demonstrated a 114% increase in citrate. Collectively, the 
metabolic profiling indicates that the old mice had enhanced proinflammatory 
metabolism. These data are consistent with our observation of significantly 
increased iNOS levels in the brain of old mice compared to that of young mice 
(Fig. 2A, 17% increase, p = 0.02). 
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We found that two of the brain metabolites related to gut microbiota were 
also significantly different between young and old cohorts. Compared to the 
young mice, old mice had significantly higher 3-indoxyl sulfate (Fig. 2B, 380% 
increase, p < 0.05) and phenol sulfate (Fig. 2C, 144% increase, p < 0.05) in their 
brain within 2 hours after their final feeding, however, the levels of the two 
metabolites returned to the baseline after 6 hours of feeding. 3-indoxyl sulfate is 
generated in the liver as a result of gut microbiome metabolism of tryptophan; 
phenol sulfate is a metabolite derived from bacterial metabolism of 
phenylalanine. The results suggest that the gut microbiome may play an 
important role in modulating brain metabolism. Because 3-indoxyl sulfate and 
phenol sulfate both are related to neurological toxicity and inflammation [274, 
275], it implies that old mice had higher neuroinflammation, which may of 
resulted from age-dependent changes in the gut microbiota. 
 
7.4.3 Impaired Neurovascular Functions with Age  
 
We found impaired BBB function in the old mice. Figure 3A shows 
representative confocal images of capillaries; the intensity of fluorescence in the 
capillary lumen reflects the amount of P-glycoprotein (P-gp), an efflux transporter 
of A. The corresponding quantitative results are shown in Figure 3B; the old 
mice had significantly reduced P-gp transport activity (p = 0.0031) compared to 
the young mice. We also measured P-gp protein expression levels (Fig. 3C). 
Similar to the results of P-gp activity, we found that the old mice had significant 
reduction in P-gp protein levels compared to the young mice (decrease to 63.7 ± 
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5.4 % over 100% young; p < 0.001; Fig. 3C). We also observed reduced CBF in 
the old mice. Figure 3D shows the representative CBF images of the young and 
old mice. The CBF level is colorized in a linear scale, indicating that the young 
mice have overall higher CBF compared to the old mice, which was confirmed by 
the quantitative global CBF values (Fig. 3E, 87% increase, p < 0.001). We did 
further CBF analyses in brain regions associated with cognitive functions (e.g., 
memory and learning) based on MRI structural imaging and mouse brain atlas. 
We found that young mice exhibited an 82% increase in CBF in the hippocampus 
(p < 0.001, Fig. 3F), compared to the old mice. 
 
7.4.4 Compromised Cognition and Increased Anxiety with Age   
 
The old mice spent significantly longer time in the closed arms compared 
to the young mice in the EPM test (Fig. 4A; 132% increase, p < 0.0001), 
indicating higher anxiety. In the NOR test, the old mice showed a significantly 
lower D2 value compared to the young group, suggesting reduced recognition 
memory (Fig. 4B, -74% decrease, p < 0.0001). In the RAWM test, the old group 
made significantly more errors in the learning phase (Block 3; 46% increase, p < 
0.01) and the initial recall phase (Block 4; 43% increase, p < 0.01), compared to 
the young group (Fig. 4C). 
 
7.5 Discussion 
 In this study, we demonstrated the age-dependent changes in brain 
metabolism, gut microbiome, vascular functions, memory and anxiety. 
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Specifically, aged mice had enhanced proinflammatory, increased ratio of 
Firmicutes to Bacteroidetes, increased bacterial alpha diversity, and body weight, 
impaired BBB and CBF, compromised learning and long-term memory, and 
increased anxiety. These deleterious changes in aging have the potential to 
increase the risk for neurological disorders and dementia, including AD. 
We found several amino acid increased in the old mice that are highly 
associated with AD, including spermidine, phenylalanine, creatine citrate, and 
methionine-related metabolites. First, spermidine levels have been found to be 
higher in the temporal cortex with a trending elevation in hippocampus and 
frontal cortex in AD patients, potentially as a response to brain injury [269]. 
Excess spermidine could exacerbate neurodegeneration as it positively 
modulates N-methyl-D-aspartate (NMDA) glutamate receptor function and disrupt 
calcium homeostasis. Second, high phenylalanine levels are also found in AD 
patients, associated with immune activation [268]. Phenylalanine disturbs 
neopterin and tryptophan metabolism, which is correlated with cognitive 
impairment [276, 277]. Third, old mice had higher creatine deposits in the brain, 
consistent with literature that creatine metabolism malfunction plays an important 
role in AD [237, 271]. Fourth, old mice had increased levels of citrate in the brain 
suggesting increased usage of fatty acid synthesis for membrane remodeling 
associated with aging due to the increased stress and inflammation that damage 
neuronal membranes [278]. Finally, the old mice had altered methionine-
associated metabolism, including increased methionine, cystathionine, cysteine, 
and cysteine-glutathione disulfide. Excessive methionine has been considered to 
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be accountable for increased mitochondrial ROS production, which in turn 
enhances oxidative stress and inflammation [277, 279, 280]. Interestingly, 
previous studies have shown that methionine restriction can lead to increased 
longevity by decreasing mitochondrial complex IV activity and accumulation of 
ROS [281, 282]. 
Accumulation of lipids in the brain is another hallmark of AD [283]. In the 
present study, we also found AD-associated fatty acids increased in the aged 
mice. First, 24(S)-hydroxycholesterol, an oxidized product of cholesterol 
produced in the brain, has been demonstrated to be elevated in AD patients and 
is hypothesized to be an early marker for distorted cholesterol status [266]. 
Second, phosphocholine has been revealed to be increased in rats during the 
early stages of AD during lesion-induced neuronal sprouting in the hippocampus 
[272]. This indicates that sprouting may occur early on in AD with 
phosphocholine as a marker. In addition, sprouting may also lead to a decline in 
energy metabolism due to energy being used for sprouting, consistent with the 
evidence of glucose metabolism decline in AD. Third, mead acid (20:3n9), an 
omega-9 fatty acid, has been demonstrated to be increased in the mid-frontal 
cortex, temporal cortex, and hippocampus of AD patients [267]. Fourth, 
docosapentaenoate (n6 DPA), an omega-6 fatty acid, has been inversely 
correlated with learning [270]. This is consistent with previous findings that oleic 
acid-enriched triglycerides were found in the brain of a triple transgenic mice 
model of AD (3xTg-AD); but when the triglycerides were inhibited, proper brain 
function was restored [284]. Further, prostaglandin D2 and E2, produced from 
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arachidonate, are generators of an inflammatory response and present in 
increased amounts in such an event, were also elevated in the old group [285]. 
Specifically, in one study, prostaglandin E2 was associated with neuronal 
oxidative damage after activation by lipopolysaccharide (LPS)[286]. LPS also can 
activate iNOS, which is consistent with our finding that old mice had significantly 
increased iNOS expression in the brain. In contrast, the aged mice showed 
reduced levels of CDP-choline, which has shown to alleviate AD symptoms by 
increasing CBF and brain electrical activity and reducing serum cytokine IL-1β 
levels [273]. Old mice also had dramatically decreased levels of 
glycerophopshorylcholine (GPC), which has been used to treat patients with 
cognitive impairment and AD [287]. Collectively, old mice exhibited a myriad of 
markers associated with inflammation and AD. 
The enhanced inflammation with age may have also occurred in the gut. 
We found that 3-indoxyl sulfate and phenol sulfate, which originate from the gut 
microbiota, were significantly elevated in the aged mice’s brains after meals. 
Significant increases of indoxyl sulfate have shown to enhance neurological 
toxicity, increase oxidative stress and ROS, and induce endothelial dysfunction 
by inhibiting endothelial proliferation and migration in vitro [288, 289]. In addition, 
phenol sulfate is derived from bacterial metabolism of phenylalanine, a marker 
for AD, as mentioned above. Next, we found a modest increase in older mice in 
the relative abundance of sequences from bacteria of the phylum Firmicutes, with 
a concomitant decrease in the relative abundance of sequences from bacteria of 
the phylum Bacteroidetes. Although neither change was statistically significant, 
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the overall change, leading to an increased Firmicutes/Bacteroidetes (F/B) ratio 
in older mice, was significant. As bacteria from the Firmicutes have been 
associated with weight-gain and those within the Bacteroidetes with weight-loss, 
this increased F/B ratio may promote body weight gain in old mice [49]. Further, 
this increased F/B ratio may lead to excessive low-grade inflammation and a 
substantial increase in energy harvesting and food intake [43, 290]. As a result, 
the F/B ratio has become a well-known marker for obesity and T2DM (Type 2 
Diabetes Mellitus) [291]. Interestingly, AD has been called Type 3 diabetes due 
to the overlapping symptoms observed in T2DM, e.g. insulin resistance and 
increased inflammation in the brain [292], along with an increased risk of 
dementia [293]. Thus, the increased F/B ratio may be indicative of an increased 
risk for AD.  
Short-chain fatty acids (SCFAs), including butyrate and propionate that 
are produced by certain bacterial species, have a dramatic impact on brain 
function. For example, butyrate has been demonstrated to prevent inflammatory 
responses via NFκB inhibition in microglia and hippocampal slice cultures [81]. 
Also, indole-3-proprionic acid (IPA), another metabolite produced by the gut 
microbiome, was demonstrated to inhibit A fibril formation in neurons and 
neuroblastoma cells [85]. On the contrary, increased Firmicutes may enhance 
trimethylamine (TMA) and its co-metabolites trimethylamine N-oxide (TMAO) 
[294]. TMAO level predicts risk for atherosclerosis and directly induces 
cardiovascular disease [80, 295-297]. 
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Reduced SCFAs has been shown to induce BBB permeability [72]. This is 
consistent with our findings that BBB function was compromised in the old mice. 
Specifically, we found the old mice had a significantly lower quantity of P-gp 
transporters in BBB, which are responsible for Aβ clearance from the brain to 
blood, indicative of an increased risk of developing AD [298]. BBB breakdown 
has been caused by elevated neuroinflammation [20] and is associated with CBF 
reduction. In line with this, we found decreased CBF in old mice. In particular, old 
mice had significantly decreased CBF in the hippocampus, the brain region that 
modulates cognitive function. Further, the old mice performed worse in the 
RAWM and NOR behavior tests than the young animals. Specifically, the old 
group performed worse in Block 3 and 4 of the RAWM compared to the young 
group, exhibiting inhibited spatial learning and long-term memory formation, 
consistent with our previous findings [129, 133]. In the NOR test, the old group 
had a worse D2 score compared to the young group, indicating a worse 
recognition memory. Taken together, our findings are consistent with the 
literature where impaired neurovascular integrity plays a critical role in 
determining cognitive functions [299]. 
Higher anxiety levels were shown in old mice compared to young mice, 
which may be also associated with brain vascular and metabolic dysfunctions 
[258-260]. Interestingly, the gut microbiome has been linked with anxiety [141]. 
Indeed, the gut and brain are connected via the enteric nervous system and have 
bi-directional communication, impacting behavior [300]. Certain bacterial species 
such as L. rhamnosus have been demonstrated to decrease anxiety like 
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symptoms and stress induced hormones [88]. Studies using oral administration 
of food-borne pathogens showed evidence that bacteria residing in the 
gastrointestinal tract can activate stress circuits through activation of vagal 
pathways [301, 302]. Exposure to a subpathogenic infection of C. jejuni 
increased anxiety-like behavioral measure in the EPM two days after infection 
[303]. These studies clearly demonstrated that inflammatory state could have 
strong influences on behavior and mental health. Conversely, treating mice with 
probiotics has been shown to reduce anxiety-like behavior; the probiotic-treated 
group showed increased entries into the open arms of the EPM compared to the 
control group [304]. Further confirming the importance of the gut microbiome in 
relation to stress, one study demonstrated germ-free mice to have an excessive 
release of stress hormones. However, when these mice were colonized with 
Bifidobacterium infantis, this response was alleviated [305]. Similar observations 
were also made in clinical trials in patients with chronic fatigue, showing that 
anxiety-like symptoms were alleviated by probiotics [306]. The study findings 
may be applicable to AD as increased anxiety levels and depression are 
commonly found preceding the onset of AD [225]. Modulating the gut microbiome 
may thus be important for reducing risk or preventing AD and other 
neurodegenerative disorders [307-310]. 
We summarize our findings with Figure 5. It shows that advancing age 
drives deleterious modifications in metabolism, gut microbiome, neurovascular 
integrity, cognition, and mental health, which may significantly enhance the risk 
for AD. Our study implies that inflammation may play a critical role in the 
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remodeling process. This is consistent with the concept of inflammaging, the 
phenomenon where innate immunity is activated, coupled with the rise of 
proinflammation with advancing age [311]. We suggest that, based on our 
results, the inflammatory responses with age are systematic; they may be 
originated from the CNS as well as the peripheral systems, e.g., from the gut. To 
promote healthy aging and prevent AD, it will thus be critical to manage low-
grade, chronic proinflammation over time. 
In future studies, it is important to determine mechanisms linking the brain 
and gut in the context of brain aging, including pathways involved in SCFAs, 
neurotransmitters, vagus nerve activity, and immune system function. As well as, 
to identify potential nutritional interventions that can promote brain-gut 
interactions, such as probiotics and prebiotics.  
We have recently shown that dietary interventions can delay brain aging 
(e.g., caloric restriction and rapamycin) and thus, it will be crucial in the future to 
determine if these dietary interventions also have a significant impact on the 
brain-gut axis [129, 133, 312]. In addition, it will be imperative to develop 
surrogate biomarkers using neuroimaging. In the present study, we used MRI to 
measure in vivo CBF, but we have also developed imaging methods to determine 
brain metabolic and anatomical integrity [313, 314]. Further, we will also use this 
state-of-the-art technology to study brain-gut axis and make our research 
strategy translatable to clinical applications. 
In conclusion, we found the inflammation-associated impact on brain 
metabolism, gut microbiome, neurovascular functions, memory, and anxiety in 
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aging mice. However, additional research needs to be conducted on the gut 
microbiome and mechanisms of the gut-brain axis. Understanding brain aging is 
imperative to identify risks, and intervention thereof, for AD. A comprehensive 
and integrative characterization of brain aging, including its crosstalk with 
peripheral systems and factors, will help to define the mechanisms underlying the 
shift from normal aging to pathological processes in the etiology of AD [309, 
310].  
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Table 7-1 Enhanced proinflammatory metabolism with age 
 
  
Classification Metabolite P Young  Old  
Amino Acids creatine 0.003 0.990 ± 0.022 1.101 ± 0.017 
 cystathionine 0.026 0.943 ± 0.072 1.316 ± 0.174 
 cysteine 0.007 1.023 ± 0.138 1.873 ± 0.262 
 cysteine-glutathione disulfide 0.013 1.008 ± 0.132 1.736 ± 0.267 
 methionine 0.001 0.915 ± 0.047 1.204 ± 0.015 
 phenylalanine 0.002 0.917 ± 0.042 1.255 ± 0.085 
 spermidine 0.016 0.910 ± 0.059 1.436 ± 0.238 
Cofactors & Vitamins citrate 0.008 0.867 ± 0.099 1.860 ± 0.381 
Lipids 24(S)-hydroxycholesterol 0.025 0.939 ± 0.027 1.135 ± 0.098 
 CDP-choline 0.037 1.002 ± 0.014 0.944 ± 0.028 
 docosapentaenoate (n6 DPA; 
22:5n6) 0.007 0.994 ± 0.019 1.215 ± 0.085 
 mead acid (20:3n9) 0.025 1.070 ± 0.068 1.367 ± 0.122 
 phosphocholine 0.024 1.076 ±0.029 1.206 ± 0.054 
 prostaglandin D2 0.009 0.682 ± 0.087 1.238 ± 0.193 
 prostaglandin E2 0.007 0.746 ± 0.076 1.341 ± 0.207 
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Table 7-1 Enhanced proinflammatory metabolism with age 
Metabolomic profiling of brain metabolites. Representative data, shown in 
scaled intensity, of the young and old groups. Data are mean ± SEM. 
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Figure 7-1 Altered gut microbiome and increased body weight with age 
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Figure 7-1 Altered gut microbiome and increased body weight with age 
 
(A) The old mice showed a higher alpha-diversity, as indicated by the 
Shannon index, than the young mice (p = 0.02). Compared with the young mice, 
the old mice had significantly increased (B) Firmicutes/Bacteroidetes ratio and 
(C) body weight. N= 39 and 28 for young and old mice, respectively. Data are 
presented as mean ± SEM. 
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Figure 7-2 Age increases inducible nitric oxide synthase (iNOS) 
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Figure 7-2 Age increases inducible nitric oxide synthase (iNOS) 
(A) The old mice had a significant increase in iNOS in the brain compared 
to the young mice (N = 7-8 per group). The old mice had acute elevations (2 
hours after feeding) in (B) 3-indoxyl sulfate and (C) phenol sulfate; those levels 
returned to baseline in 4 hours (N = 6 and 4 for young and old mice, 
respectively). 
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Figure 7-3 Impaired neurovascular functions with age 
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Figure 7-3 Impaired neurovascular functions with age 
(A) Representative confocal images showing decreased luminal 
accumulation of NBD-CSA fluorescence (green) in brain capillaries isolated from 
the old mice compared to young mice, indicating reduced P-gp activity. (B) 
Corresponding quantitative fluorescence data; images are shown in arbitrary 
fluorescence units (scale 0-255). Data are mean ± SEM for 10 capillaries from 
one preparation of 10 mice. (C) Western blotting (WB) for P-gp from the cortical 
vasculature, β-Actin was used as loading control (top); corresponding values are 
shown in the table (bottom). The WB data from the old mice were normalized to 
β-Actin and compared to the young mice (100%), **p < 0.01. (D) CBF maps 
superimposed on structural images; the color code indicates the level of CBF in a 
linear scale. Quantitative CBF (ml/g/min) obtained from (E) the whole brain and 
(F) hippocampus (N = 12 per group). Data are mean ± SEM. 
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Figure 7-4 Compromised cognition and increased anxiety with age 
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Figure 7-4 Compromised cognition and increased anxiety with age 
 
(A) The elevated plus maze found the old mice to have a significantly higher 
closed arm duration compared to the young group. (B) The novel object 
recognition test found the old group had a significantly lower recognition index, or 
D2, than the young group. (C) The average errors made by the young and old 
mice during the radial arm water maze split into 6 blocks. The significant 
difference between the two groups in average errors corrected showing in Block 
3 (p = 0.0307) and Block 4 (p = 0.0045). N = 22 and 18 for young and old mice, 
respectively. Data are presented as mean ± SEM. 
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Figure 7-5 Association of age-dependent changes 
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Figure 7-5 Association of age-dependent changes 
 
Proposed associations of age-dependent changes in brain metabolism, 
vascular integrity, gut microbiome, cognition and anxiety levels. Inflammation in 
aging, or inflammaging, might play a critical role in be a driving the deleterious 
changes in the brain and gut. 
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